Intellipharmaceutics International (IPCIF) 20-F 18 Feb 14 2013 FY Annual report (foreign) Financial data

Document_And_Entity_Informatio

Document And Entity Information	12 Months Ended
	Nov. 30, 2013
Document and Entity Information [Abstract]	'
Entity Registrant Name	'Intellipharmaceutics International Inc.
Document Type	'20-F
Current Fiscal Year End Date	'--11-30
Entity Common Stock, Shares Outstanding	21,430,611
Amendment Flag	'false
Entity Central Index Key	'0001474835
Entity Current Reporting Status	'Yes
Entity Voluntary Filers	'No
Entity Filer Category	'Non-accelerated Filer
Entity Well-known Seasoned Issuer	'No
Document Period End Date	30-Nov-13
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Nov. 30, 2013	Nov. 30, 2012
Current	'	'
Cash and cash equivalents	$760,586	$497,016
Accounts receivable (Note 4)	1,475,745	2,778
Investment tax credits	179,551	301,932
Prepaid expenses, sundry and other assets	312,533	137,449
	2,728,415	939,175
Deferred offering costs (Note 10)	419,777	'
Property and equipment, net (Note 5)	1,231,309	1,535,703
	4,379,501	2,474,878
Current	'	'
Accounts payable	810,381	512,360
Accrued liabilities (Note 6)	669,321	224,797
Employee costs payable (Note 8)	508,616	663,222
Current portion of capital lease obligations (Note 9)	43,264	51,524
Due to related parties (Note 7)	759,564	783,717
	2,791,146	2,235,620
Convertible debenture (Note 7)	2,105,406	'
Capital lease obligations (Note 9)	'	46,242
Warrant liabilities (Note 14)	5,438,022	1,960,893
	10,334,574	4,242,755
Authorized	'	'
Unlimited common shares without par value (in Shares)	'	'
Unlimited preference shares (in Shares)	'	'
Issued and outstanding	'	'
21,430,611 common shares (2012 - 17,906,937)	11,721,152	6,128,697
Additional paid-in capital (Note 19)	23,619,055	22,428,120
Accumulated other comprehensive loss	284,421	-240,010
Accumulated deficit	-41,579,701	-30,084,684
	-5,955,073	-1,767,877
Contingencies (Note 16)	'	'
	$4,379,501	$2,474,878

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Nov. 30, 2013	Nov. 30, 2012
Unlimited common shares, par value (in Dollars per share)	'	'
Common shares, Issued (in Shares)	21,430,611	17,906,937
Common shares, Outstanding (in Shares)	21,430,611	17,906,937

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
	Nov. 30, 2013		Nov. 30, 2012		Nov. 30, 2011
Revenues	'		'		'
Licensing (Note 3)	$1,481,719		'		'
Milestone	43,209		'		'
Research and development	1,527,474		107,091		501,814
Other incidental services	2,546		'		'
	1,527,474		107,091		501,814
Expenses	'		'		'
Research and development	5,076,236		5,992,417		5,125,608
Selling, general and administrative	2,873,091		3,672,313		2,925,454
Depreciation (Note 5)	396,814		452,303		227,456
Write-down on long lived assets (Note 5)	'		107,123		'
	8,346,141		10,224,156		8,278,518
Loss from operations	-6,818,667		-10,117,065		-7,776,704
Fair value adjustment of derivative liabilities (Note 7 and 14)	-3,889,683	[1]	3,841,233	[1]	5,346,878
Financing expense (Note 10)	-115,056		'		-2,357,732
Net foreign exchange (loss) gain	-359,554		181,682		-70,036
Interest income	2,839		20,691		60,790
Interest expense	-314,896		-63,406		-83,473
Net loss	-11,495,017		-6,136,865		-4,880,277
Other comprehensive income (loss)	'		'		'
Foreign exchange translation adjustment	524,431		-124,975		110,441
Comprehensive loss	($10,970,586)		($6,261,840)		($4,769,836)
Loss per common share, basic and diluted (in Dollars per share)	($0.58)		($0.36)		($0.33)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	19,671,093		17,258,686		14,994,118
[1]	The total net loss related to the conversion option and warrant liability has been recorded under fair value adjustment derivative liabilities on the consolidated statements of operations and comprehensive loss.

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Deficiency (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Balance	($1,767,877)	($3,093,030)	$92,956
Issuance of common shares	5,460,892	5,000,000	'
Share issuance cost and cost adjustments	-857,278	-779,271	'
Shares issued for options exercised	5,965	'	93,165
Shares issued for options exercised (in Shares)	3,500	0	25,000
Issuance of shares on exercise of warrants (Note 14)	980,382	'	'
Stock options to employees	1,017,908	2,251,325	674,746
Stock options to non-management board members	135,974	72,520	27,714
DSU's to non-management board members	39,547	36,727	33,101
Issuance of shares on exercise of cashless warrants	'	1,005,692	755,124
Other comprehensive gain (loss)	524,431	-124,975	110,441
Net loss	-11,495,017	-6,136,865	-4,880,277
Net Period Change in Consolidated statements of operations and comprehensive loss	-4,187,196	1,325,153	-3,185,986
Balance	-5,955,073	-1,767,877	-3,093,030
Special Voting Shares [Member]	'	'	'
Balance	6,128,697	902,276	16,969
Balance (in Shares)	17,906,937	15,908,444	10,907,054
Issuance of common shares (in Shares)	3,315,000	1,818,182	4,800,000
Issuance of common shares	5,460,892	5,000,000	'
Share issuance cost and cost adjustments	-857,278	-779,271	'
Shares issued for options exercised	8,459	'	130,183
Shares issued for options exercised (in Shares)	3,500	'	25,000
Issuance of shares on exercise of warrants (Note 14)	980,382	'	'
Issuance of shares on exercise of warrants (Note 14) (in Shares)	205,175	'	'
Issuance of shares on exercise of cashless warrants	'	1,005,692	755,124
Issuance of shares on exercise of cashless warrants (in Shares)	'	180,315	176,469
Cancellation on shares exchanged (in Shares)	-1	-4	-79
Net Period Change in Consolidated statements of operations and comprehensive loss	5,592,455	5,226,421	885,307
Net Period Change in Consolidated statements of operations and comprehensive loss (in Shares)	3,523,674	1,998,493	5,001,390
Balance	11,721,152	6,128,697	902,276
Balance (in Shares)	21,430,611	17,906,937	15,908,444
Additional Paid-in Capital [Member]	'	'	'
Balance	22,428,120	20,067,548	19,369,005
Shares issued for options exercised	-2,494	'	-37,018
Stock options to employees	1,017,908	2,251,325	674,746
Stock options to non-management board members	135,974	72,520	27,714
DSU's to non-management board members	39,547	36,727	33,101
Net Period Change in Consolidated statements of operations and comprehensive loss	1,190,935	2,360,572	698,543
Balance	23,619,055	22,428,120	20,067,548
Accumulated Other Comprehensive Income (Loss) [Member]	'	'	'
Balance	-240,010	-115,035	-225,476
Other comprehensive gain (loss)	524,431	-124,975	110,441
Net Period Change in Consolidated statements of operations and comprehensive loss	524,431	-124,975	110,441
Balance	284,421	-240,010	-115,035
Retained Earnings [Member]	'	'	'
Balance	-30,084,684	-23,947,819	-19,067,542
Net loss	-11,495,017	-6,136,865	-4,880,277
Net Period Change in Consolidated statements of operations and comprehensive loss	-11,495,017	-6,136,865	-4,880,277
Balance	($41,579,701)	($30,084,684)	($23,947,819)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Loss	($11,495,017)	($6,136,865)	($4,880,277)
Items not affecting cash	'	'	'
Depreciation	396,814	452,303	227,456
Stock-based compensation (Note 11)	1,153,882	2,323,845	702,460
Deferred share units (Note 12)	39,548	36,727	33,101
Interest accrual	43,538	45,278	7,739
Fair value adjustment of derivative liabilities (Note 7 and 14)	3,889,683	-3,841,233	-5,346,878
Write-down on long lived assets (Note 5)	'	107,123	'
Financing expense (Note 10)	115,056	'	884,587
Unrealized foreign exchange loss (gain)	403,180	-145,724	203,604
Change in non-cash operating assets & liabilities	'	'	'
Accounts receivable	-1,472,966	605	-1,764
Investment tax credits	106,744	96,264	869,406
Prepaid expenses and sundry assets	-181,402	-10,206	17,189
Accounts payable and accrued liabilities	74,144	-475,387	203,743
Deferred revenue	'	-107,091	98,186
Cash flows used in operating activities	-6,926,796	-7,654,361	-6,981,448
Financing activities	'	'	'
Payments to related parties (Note 7)	'	'	-801,551
Repayment of capital lease obligations	-49,989	-44,364	-22,452
Issuance of shares on exercise of stock options (Note 11)	5,965	'	93,165
Proceeds from issuance of shares and warrants, gross	6,196,800	5,000,000	12,000,000
Share issuance cost (Note 10)	-836,099	-779,271	'
Cash flows provided from financing activities	7,328,420	4,363,865	11,269,162
Proceeds from issuance of shares on exercise of warrants (Note 14)	511,743	187,500	'
Proceeds from convertible debenture (Note 7)	1,500,000	'	'
Investing activity	'	'	'
Purchase of property and equipment	-122,017	-1,036,092	-262,142
Cash flows used in investing activities	-122,017	-1,036,092	-262,142
Effect of foreign exchange gain on cash held in foreign currency	-16,037	6,516	2,380
Increase (decrease) in cash and cash equivalents	263,570	-4,320,072	4,027,952
Cash and cash equivalents, beginning of year	497,016	4,817,088	789,136
Cash and cash equivalents, end of year	760,586	497,016	4,817,088
Supplemental cash flow information	'	'	'
Interest paid (Note 7)	176,311	39,173	163,099
Taxes paid	'	'	'

Note_1_Nature_of_Operations

Note 1 - Nature of Operations	12 Months Ended
	Nov. 30, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1	Nature of operations
	Intellipharmaceutics International Inc. (“IPC” or the “Company”) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
	On October 22, 2009, IntelliPharmaCeutics Ltd. (“IPC Ltd. “) and Vasogen Inc. (“Vasogen”) completed a court approved plan of arrangement and merger (the “IPC Arrangement Agreement”), resulting in the formation of the Company, which is incorporated under the laws of Canada. The Company’s common shares are traded on the Toronto Stock Exchange and NASDAQ.
	The Company earns revenues from development contracts which provide upfront fees, milestone payments, reimbursement of certain expenditures and licensing income upon commercialization of its products. In November 2013, U.S. Food and Drug Administration (“FDA”) granted the Company final approval to market the Company’s first product, dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths.
	The Company has incurred losses from operations since inception, and has an accumulated deficit of $41,579,701 as at November 30, 2013 (November 30, 2012 and 2011 - $30,084,684 and $23,947,819) respectively. The Company has funded its research and development activities principally through the issuance of securities, loans from related parties, funds from the IPC Arrangement Agreement and funds received under development agreements. There is no certainty that any funding will be available going forward.
	Going concern
	The consolidated financial statements are prepared on a going concern basis and substantial doubt exists on the appropriateness of this. In order for the Company to continue operations at existing levels and fund any significant expansion of its operation, the Company will require significant additional capital.  Although there can be no assurances, such financing may come from revenues from proceeds of the Company’s at-the-market offering program, and from sales of the Company’s dexmethylphenidate hydrochloride extended-release products. Other potential sources of capital may include collection of anticipated revenues resulting from future commercialization activities, development agreements or marketing license agreements, cost savings associated with managing operating expense levels, equity and/or debt financings, and/or new strategic partnership agreements funding some or all costs of development, although there can be no assurance that the Company will be able to obtain any such capital on terms or in amounts sufficient to meet its needs or at all.  The availability of equity or debt financing will be affected by, among other things, the results of the Company’s research and development, its ability to obtain regulatory approvals, the market acceptance of its products, the state of the capital markets generally, strategic alliance agreements, and other relevant commercial considerations.  In addition, if the Company raises additional funds by issuing equity securities, its then existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that would restrict its operations.  In the event that the Company does not obtain additional capital, there may be substantial doubt about its ability to continue as a going concern and realize its assets and pay its liabilities as they become due.  Any failure by the Company to raise additional funds on terms favorable to the Company, or at all, may require the Company to significantly change or curtail its current or planned operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated, and could result in its not taking advantage of business opportunities, in the termination or delay of clinical trials for one or more of its product candidates, in curtailment of its product development programs designed to identify new product candidates, in the sale or assignment of rights to its technologies, products or product candidates, and/or its inability to file abbreviated new drug applications (“ANDAs”) or New Drug Applications (“NDAs”) at all or in time to competitively market its products or product candidates.
	The audited consolidated financial statements do not include any adjustments that might result from the outcome of uncertainties described above. If the going concern assumption was not appropriate for these financial statements, then adjustments would be necessary to the carrying values of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments could be material.

Note_2_Basis_of_Presentation

Note 2 - Basis of Presentation	12 Months Ended
	Nov. 30, 2013
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	2	Basis of presentation
		(a)	Basis of consolidation
	These consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiaries, IPC Ltd., Intellipharmaceutics Corp. (“IPC Corp”), and Vasogen Corp. These consolidated financial statements also include the results of Vasogen Ireland Ltd. up to June 27, 2012, the date of its dissolution.
	All inter-company accounts and transactions have been eliminated on consolidation.
		(b)	Use of estimates
	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates.
	Areas where significant judgment is involved in making estimates are: the determination of estimated useful lives of property and equipment; the fair values of financial assets and liabilities; the determination of units of accounting for revenue recognition; the accrual of licensing and milestone revenue; the fair value of stock options and the determination of performance criteria for expensing stock-based payments; the fair value of warrants; the fair value of conversion option embedded derivative; evaluation of income tax positions; the determination of valuation allowances; the determination of investment tax credits; deferred revenue; forecasting future cash flows for assessing whether there are any impairments of long-lived assets; and the going concern assumption.

Note_3_Significant_Accounting_

Note 3 - Significant Accounting Policies	12 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	3	Significant accounting policies
		(a)	Cash and cash equivalents
	The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. Cash equivalent balances consist of bankers’ acceptances and bank accounts with variable, market rates of interest.
	The financial risks associated with these instruments are minimal and the Company has not experienced any losses from investments in these securities. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
		(b)	Accounts receivable
	The Company reviews its sales and accounts receivable aging and determines whether an allowance for doubtful accounts is required.
		(c)	Financial instruments
	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are classified as liabilities, the derivative instrument is initially recorded at its fair value using the appropriate valuation methodology and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss.
		(d)	Investment tax credits
	The investment tax credits (“ITC") receivable are amounts considered recoverable from the Canadian federal and provincial governments under the Scientific Research & Experimental Development (“SR&ED”) incentive program. The amounts claimed under the program represent the amounts submitted by management based on research and development costs incurred during the year up to November 30, 2013. Realization is subject to government approval. Any adjustment to the amounts claimed will be recognized in the year in which the adjustment occurs. Refundable ITCs claimed relating to capital expenditures are credited to property and equipment. Refundable ITCs claimed relating to current expenditures are netted against research and development expenditures.
		(e)	Property and equipment
	Property and equipment are recorded at cost. Equipment acquired under capital leases are recorded net of imputed interest, based upon the net present value of future payments. Assets under capital leases are pledged as collateral for the related lease obligation. Repairs and maintenance expenditures are charged to operations; major betterments and replacements are capitalized. Depreciation bases and rates are as follows:
	Assets	Basis	Rate
	Computer equipment	Declining balance	30%
	Computer software	Declining balance	50%
	Furniture and fixtures	Declining balance	20%
	Laboratory equipment	Declining balance	20%
	Leasehold improvements	Straight line	Over term of lease
	Leasehold improvements and assets acquired under capital leases are depreciated over the term of their useful lives or the lease period, whichever is shorter. The charge to operations resulting from depreciation of assets acquired under capital leases is included with depreciation expense.
		(f)	Impairment of long-lived assets
	Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on internal or external appraisals.
		(g)	Warrants
	The Company issued warrants as described in Notes 10 and 14.  The warrants are presented as a liability because they do not meet the criteria of Accounting Standard Codification (“ASC”) topic 480 for equity classification. Subsequent changes in the fair value of the warrants are recorded in the consolidated statements of operations and comprehensive loss.
		(h)	Convertible debenture
	The Company issued a convertible debenture as described in Note 7.  The conversion option is bifurcated from its host contract and the fair value of the conversion option is characterized as an embedded derivative upon issuance as it meets the criteria of ASC Topic ASC815-15-25-1 Embedded Derivatives. Subsequent changes in the fair value of the embedded derivative are recorded in the consolidated statements of operations and comprehensive loss. The proceeds received from the Debenture less the initial amount allocated to the embedded derivative are allocated to the liability and are accreted over the life of the Debenture using the imputed rate of interest.
		(i)	Revenue recognition
	The Company accounts for revenue in accordance with the provision of ASC topic 605 Revenue Recognition. The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing payments on sales of resulting products and other incidental services. Revenue is realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed or determinable, and collectability is reasonably assured. From time to time, the Company enters into transactions that represent multiple-element arrangements. Management evaluates arrangements with multiple deliverables to determine whether the deliverables represent one or more units of accounting for the purpose of revenue recognition.
	A delivered item is considered a separate unit of accounting if the delivered item has stand-alone value to the customer, the fair value of any undelivered items can be reliably determined, and the delivery of undelivered items is probable and substantially in the Company's control.
	The relevant revenue recognition accounting policy is applied to each separate unit of accounting.
	Licensing
	The Company recognizes license revenue from the licensing of the Company's drug delivery technologies, products and product candidates. Licensing revenue is recognized as earned in accordance with the contract terms when the amounts can be reasonably estimated and collectability is reasonably assured.
	The Company has a License and Commercialization Agreement with Par. Under the exclusive territorial license rights granted to Par, the agreement requires that Par manufacture, promote, market, sell and distribute the product. License revenue amounts receivable by the Company under this agreement are calculated and reported to the Company by Par, with such amounts generally based upon net product sales and net profit which include estimates for chargebacks, rebates, product returns, and other adjustments.  License revenue payments received by the Company from Par under this agreement are not subject to deductions for chargebacks, rebates, product returns, and other pricing adjustments.  Based on this arrangement and the guidance per ASC topic 605, the Company records license revenue as earned in the consolidated statements of operations and comprehensive loss.
	Milestones
	In connection with the License and Commercialization Agreement with Par, if the Company’s product is the only generic in the market or if there is only one generic competitor, a milestone payment is earned.  Revenue is recognized when the milestones are achieved. The milestone method recognizes revenue on substantive milestone payments in the period the milestone is achieved. Milestones are considered substantive if all of the following conditions are met: (i) the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) the milestone relates solely to past performance; and (iii) the milestone is reasonable relative to all of the deliverables and payment terms within the arrangement. Nonsubstantive milestone payments that might be paid to the Company based on the passage of time or as a result of a partner’s performance are allocated to the units of accounting within the arrangement; they are recognized as revenue in a manner similar to those units of accounting.
	Research and development
	Under arrangements where the license fees and research and development activities can be accounted for as a separate unit of accounting, non-refundable upfront license fees are deferred and recognized as revenue on a straight-line basis over the expected term of the Company's continued involvement in the research and development process.
	Deferred revenue represents the funds received from clients, for which the revenues have not yet been earned, as the milestones have not been achieved, or in the case of upfront fees for drug development, where the work remains to be completed.
	Other incidental services
	Incidental services which we may provide from time to time include, consulting advice provided to other organizations regarding FDA standards. Revenue is earned and realized when all of the following conditions are met:  (i) there is persuasive evidence of an arrangement; (ii) service has been rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.
		(j)	Research and development costs
	Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. However, materials and equipment are capitalized and amortized over their useful lives if they have alternative future uses.
		(k)	Income taxes
	The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for losses and tax credit carry forwards. Significant judgment is required in determining whether deferred tax assets will be realized in full or in part. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the year that includes the date of enactments. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized.
	The Company accounts in accordance with ASC topic 740-10. This ASC topic requires that uncertain tax positions are evaluated in a two-step process, whereby (i) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (ii) those tax positions that meet the more likely than not recognition threshold, the Company would recognize the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the related tax authority. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The cumulative effects of the application of the provisions of ASC topic 740-10 are described in Note 15.
	The Company records any interest related to income taxes in interest expense and penalties in selling, general and administrative expense.
		(l)	Share issue costs
	Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Share issue costs incurred in respect of issuing common shares in the at-the-market offering facility have been deferred and are recorded as deferred offering costs in 2013.
		(m)	Translation of foreign currencies
	The consolidated financial statements of the Company are measured using the Canadian dollar as the functional currency. The Company's reporting currency is the U.S. dollar. The financial results of the Canadian operations are measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operations have been translated at year end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the consolidated financial statements of the Canadian operations are included as part of accumulated other comprehensive (loss) income, a separate component of shareholders' equity.
	In respect of other transactions denominated in currencies other than the respective entities' functional currencies, the monetary assets and liabilities are translated at the year end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the consolidated statements of operations and comprehensive loss.
		(n)	Stock-based compensation
	The Company has a stock-based compensation plan which authorizes the granting of various equity-based incentives including stock options and restricted share units (“RSU”s). The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the expected life of the option. The provisions of the Company's stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity.
	Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation expense is recorded in the consolidated statements of operations and comprehensive loss under research and development expense and under selling, general and administration expense. Note 11 provides supplemental disclosure of the Company's stock options.
		(o)	Deferred Share Units
	Deferred Share Units (“DSU”s) are valued based on the trading price of the Company’s common shares on the Toronto Stock Exchange.  The Company records the value of the DSU’s owing to non-management board members in the consolidated statement of deficiency.
		(p)	Loss per share
	Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.
	The dilutive effect of stock options is determined using the treasury stock method. Stock options and warrants to purchase 7,034,647, 7,830,059 and 7,876,229 common shares of the Company during fiscal 2013, 2012, and 2011, respectively, were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended November 30, 2013, 2012 and 2011 as the effect would be anti-dilutive.
		(q)	Comprehensive loss
	The Company follows ASC topic 810-10. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity. Other than foreign exchange gains and losses arising from cumulative translation adjustments, the Company has no other comprehensive loss items.
		(r)	Fair value measurement
	Under ASC topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows:
	●	Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	●	Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.
	●	Level 3 - Unobservable inputs for the asset or liability.
The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
	(s)	Recently adopted accounting pronouncements
In February 2013, the FASB provided amendments to Accounting Standards Update (“ASU”) No. 2013-02 “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. Early adoption is permitted. The Company adopted the amendments on March 1, 2013. The adoption did not have an impact on the Company’s financial position, results of operations or cash flow.
	(t)	Future Accounting pronouncements
In March 2013, the FASB provided amendments to ASU No. 2013-05 “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (a consensus of the FASB Emerging Issues Task Force)”. The amendments are effective prospectively for reporting periods beginning after December 15, 2013. The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations or cash flow.
In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for an net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. The ASU does not require new recurring disclosures. It is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption and retrospective application are permitted.  The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations or cash flow.

Note_4_Accounts_Receivable

Note 4 - Accounts Receivable	12 Months Ended
	Nov. 30, 2013
Receivables [Abstract]	'
Financing Receivables [Text Block]	'
	4	Accounts receivable
	The Company currently has no debt agreements in place whereby any amount of receivables serve as collateral. The Company has no off-balance-sheet credit exposures and has no foreclosed or repossessed assets. The Company has had no impaired loans related to receivables and has identified no loss contingencies related to the receivables at November 30, 2013 and November 30, 2012. Risks and uncertainties and credit quality information related to accounts receivable have been disclosed in Note 17.

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
	Nov. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	5	Property and equipment
			30-Nov-13
			Cost		Accumulated		Net book
					amortization		value
			$		$		$
	Computer equipment			228,854		177,831		51,023
	Computer software			113,862		79,603		34,259
	Furniture and fixtures			126,690		91,335		35,355
	Laboratory equipment			2,378,621		1,404,479		974,142
	Leasehold improvements			1,111,731		1,087,083		24,648
	Laboratory equipment under capital lease			202,584		100,138		102,446
	Computer equipment under capital lease			76,458		67,022		9,436
				4,238,800		3,007,491		1,231,309
			30-Nov-12
			Cost		Accumulated		Net book
					amortization		value
			$		$		$
	Computer equipment			243,798		188,935		54,863
	Computer software			126,568		53,916		72,652
	Furniture and fixtures			140,829		98,091		42,738
	Laboratory equipment			2,602,478		1,383,709		1,218,769
	Leasehold improvements			1,108,246		1,108,246		-
	Laboratory equipment under capital lease			225,192		88,617		136,575
	Computer equipment under capital lease			84,990		74,884		10,106
				4,532,101		2,996,398		1,535,703
	Depreciation for the year ended November 30, 2013 was $396,814 (2012 - $452,303; 2011 - $227,456).
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment is assessed by comparing the carrying amount of an asset with the sum of the undiscounted cash flows expected from its use and disposal, and as such requires the Company to make significant estimates on expected revenues from the commercialization of its products and services and the related expenses. The Company records a write-down for long-lived assets which have been abandoned and do not have any residual value. For the year ended November 30, 2013, the Company recorded a $Nil write-down of long-lived assets (2012 - $107,123; 2011 – $Nil).

Note_6_Accrued_Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Nov. 30, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6	Accrued liabilities
			November 30,		November 30,
			2013		2012
			$		$
	Professional fees			468,986		116,179
	Other			200,335		108,618
				669,321		224,797

Note_7_Due_to_Related_Parties

Note 7 - Due to Related Parties	12 Months Ended
	Nov. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	7	Due to related parties
	Amounts due to the related parties are payable to entities controlled by two shareholders who are also officers and directors of the Company.
			November 30,		November 30,
			2013		2012
			$		$
	Promissory note payable to two directors and officers of the Company, unsecured, 6% annual interest rate on the outstanding loan balance (i) (2013 - C$778,491; 2012 - C$750,534)			733,042		755,368
	Note payable to an entity controlled by shareholders, officers and directors of the Company, unsecured, non-interest bearing with no fixed repayment terms (2013 - C$28,167; 2012 - C$28,167)			26,522		28,349
				759,564		783,717
	Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly(ii)			2,105,406		-
		(i)	Promissory note payable
	The promissory note dated September 10, 2004 issued by IPC Corp to Dr. Isa Odidi and Dr. Amina Odidi (the “Promissory Note”), principal shareholders, directors and executive officers of the Company was amended effective October 22, 2009 (“effective date”), to provide that the principal amount thereof shall be payable when payment is required solely out of (i) revenues earned by IPC Corp following the effective date, and/or proceeds received by any IPC Company from any offering of its securities following the effective date, other than the proceeds from the transactions completed in February 2011, March 2012, March 2013 and July 2013 (Note 10) and/or amounts received by IPC Corp for scientific research tax credits of IPC Corp and (ii) up to C$800,000 from the Net Cash (as defined in the IPC Arrangement Agreement). During the year ended November 30, 2013, no principal repayment was made (2012 - $Nil; 2011 -$801,551) and interest payment of $16,640 (C$17,671) (2012 - $39,173; 2011 - $163,099) in respect of the promissory note was made by the Company in accordance with the terms of the IPC Arrangement Agreement.
	Interest expense on the promissory note payable to related parties for the year ended November 30, 2013 is $43,538 (2012  - $45,278; 2011 - $73,011) and has been included in the consolidated statement of operations and comprehensive loss.
		(ii)	Convertible debenture
	On January 10, 2013, the Company completed a private placement financing (the "Financing") of an unsecured convertible debenture in the principal amount of $1.5 million (the "Debenture"), which will mature January 1, 2015. The Debenture bears interest at a rate of 12% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into 500,000 common shares at a conversion price of $3.00 per common share at the option of the holder.
	Dr. Isa Odidi and Dr. Amina Odidi, principal shareholders, directors and executive officers of the Company purchased the Debenture and provided the Company with the $1.5 million of the proceeds for the Debenture.
	The conversion price of the Debenture is in U.S. dollars and IPC’s functional currency is Canadian dollars. Under U.S. GAAP where the conversion price of the Debenture is denominated in a currency other than an entity's functional currency, the conversion option meets the definition of an embedded derivative. The conversion option is bifurcated from its host contract and the fair value of the conversion option characterized as an embedded derivative upon issuance. The embedded derivative is presented together on a combined basis with the host contract. The derivative is re-measured at the end of every reporting period with the change in value reported in the consolidated statements of operations and comprehensive loss.
	The proceeds received from the Debenture less the initial amount allocated to the embedded derivative were allocated to the liability and are accreted over the life of the Debenture using the imputed rate of interest.
	The fair value of the conversion option at January 10, 2013 using the Black-Scholes Option Pricing Model were initially estimated to be $220,100, using volatility of 46.6%, risk-free interest rate of 0.26%, expected life of two years, and dividend yield of Nil. The fair value of the conversion option at November 30, 2013 using the Black-Scholes Option Pricing Model was estimated to be $728,950, using volatility of 64.6%, risk-free interest rate of 0.12%, expected life of 1.1 years, and dividend yield of Nil.  This amount has been recorded in the convertible debenture line on the consolidated balance sheet. The change in fair value of the conversion option from the previously recorded amount to the year ended November 30, 2013 is a loss of $533,149 (2012 - $Nil; 2011 - $Nil), and has been recorded as a fair value adjustment of derivative liabilities in the consolidated statements of operations and comprehensive loss.
	The proceeds of $1.5 million less the initial fair value of the conversion option embedded derivative of $220,100, totaled $1,279,900 and is accreted at an annual imputed interest rate of 8%, over the life of the Debenture.
	Accreted interest expense during year ended November 30, 2013 is $96,556 (2012 - $Nil; 2011 -$Nil), and has been included in the consolidated statements of operations and comprehensive loss. In addition, the coupon interest on the Debenture for the year ended November 30, 2013 is $159,671 (2012 - $Nil; 2011 - $Nil), and has also been included in the consolidated statements of operations and comprehensive loss.
	As described in Note 8, the Company had salaries payable to the two principal shareholders.

Note_8_Employee_Costs_Payable

Note 8 - Employee Costs Payable	12 Months Ended
	Nov. 30, 2013
Compensation Related Costs [Abstract]	'
Compensation Related Costs, General [Text Block]	'
	8	Employee costs payable
	As at November 30, 2013, the Company had $336,327 (2012 - $472,619) salaries payable to Dr. Isa Odidi and Dr. Amina Odidi, principal shareholders, directors and executive officers of the Company and $172,289 (2012 - $190,603) for other amounts payable to certain employees.  These balances are due on demand and therefore presented as current in nature.

Note_9_Lease_Obligations

Note 9 - Lease Obligations	12 Months Ended
	Nov. 30, 2013
Leases, Capital [Abstract]	'
Capital Leases in Financial Statements of Lessee Disclosure [Text Block]	'
	9	Lease obligations
	The Company leases facilities under an operating lease which expires in November 2014, with an option to extend the lease on comparable terms for five additional years.  The Company also leases various computers and equipment under capital leases. Future minimum lease payments under leases with terms of one year or more are as follows at November 30, 2013:
	Year ending November 30,		Capital		Operating
			Lease		Lease
			$		$
	2014			46,079		84,356
				46,079		84,356
	Less: amounts representing interest at 14%			2,815		-
				43,264		84,356
	Less: current portion			43,264		84,356
	Balance, long-term portion			-		-

Note_10_Capital_Stock

Note 10 - Capital Stock	12 Months Ended
	Nov. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	10	Capital stock
	Authorized, issued and outstanding
		(a)	The Company is authorized to issue an unlimited number of common shares, all without nominal or par value and an unlimited number of preference shares. As at November 30, 2013 the Company has 21,430,611 (2012 – 17,906,937) common shares issued and outstanding, and no preference shares issued and outstanding.
	Two officers and directors of IPC owned directly and through their family holding company (“Odidi Holdco”) 5,997,751 (2012 - 6,005,751) common shares or approximately 28% (2012 – 34%) of IPC.
	Each common share of the Company entitles the holder thereof to one vote at any meeting of shareholders of the Company, except meetings at which only holders of a specified class of shares are entitled to vote.
	Common shares of the Company are entitled to receive, as and when declared by the board of directors of the Company, dividends in such amounts as shall be determined by the board. The holders of common shares of the Company have the right to receive the remaining property of the Company in the event of liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary.
	The preference shares may at any time and from time to time be issued in one or more series. The board of directors will, by resolution, from time to time, before the issue thereof, fix the rights, privileges, restrictions and conditions attaching to the preference shares of each series. Except as required by law, the holders of any series of preference shares will not as such be entitled to receive notice of, attend or vote at any meeting of the shareholders of the Company. Holders of preference shares will be entitled to preference with respect to payment of dividends and the distribution of assets in the event of liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, on such shares over the common shares of the Company and over any other shares ranking junior to the preference shares.
		(b)	On February 1, 2011, the Company completed a private offering for the sale and issuance of 4,800,000 units of the Company. Each unit consisted of one share of common stock, a five year Series A common share purchase warrant to purchase one half of a share of common stock at an exercise price of $2.50 per whole share and a two year Series B common share purchase warrant to purchase one half of a share of common stock at an exercise price of $2.50 per whole share for gross proceeds of $12,000,000.   The Company also issued to the placement agents 96,000 warrants to purchase a share of common stock at an exercise price of $3.125 per whole share.
	The holders of Series A and Series B common share purchase warrants and placement agents warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of shares for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price.
	Under U.S. GAAP where the strike price of the warrants is denominated in a currency other than an entity's functional currency, the warrants would not be considered indexed to the entity’s own stock, and would consequently be considered to be a derivative liability. Also under U.S. GAAP, warrants with the cashless exercise option satisfying the explicit net settlement criteria are considered a derivative liability.
	The Series A, Series B common share purchase warrants and placement agents warrants are denominated in U.S. dollars and IPC’s functional currency is Canadian dollars. As a result, the Company determined that these warrants are not considered indexed to the Company’s own stock and characterized the fair value of these warrants as derivative liabilities upon issuance. The derivative has been subsequently marked to market through the consolidated statements of operations and comprehensive loss.
	The Company incurred financing expenses of $2,357,732, which includes placement agent warrants with a fair value of $229,005 and $655,582 as the cost of the private offering.
	The Company determined that the fair value of the warrant liability at issuance to be $12,655,582 based upon a Black-Scholes Options Pricing Model calculation (Note 14). The Company recorded the full value of the derivative as a liability at issuance with an offset to valuation discount. As the fair value of the liability of $12,655,582 exceeded the proceeds of $12,000,000, the excess of the liability over the proceeds amount of $655,582 was considered to be a cost of the private offering, which was included in the financing expenses.
		(c)	In March 2012, the Company completed a registered direct common share offering for gross proceeds of $5,000,000. The Company sold an aggregate of 1,818,182 shares to U.S. institutional investors at a price of $2.75 per share. Professional, regulatory and other costs in the amount of $779,271 directly attributable to the common share offering have been recorded as share issuance costs in shareholders’ deficiency.
		(d)	In March 2013, the Company completed a registered direct unit offering for gross proceeds of $3,121,800 at a price of $1.72 per unit. The Company sold units comprised of an aggregate of 1,815,000 common shares and warrants to purchase an additional 453,750 common shares. The warrants are exercisable for a term of five years and an exercise price of $2.10 per common share. After placement agent fees and offering expenses, the Company received net proceeds from the offering of approximately $2.7 million. The Company determined the fair value of the warrant liability at issuance to be $407,558 using the Black-Scholes Option Pricing Model (Note 14). The direct costs related to the issuance of the common shares were $389,289 and were recorded as an offset against shareholders’ deficiency and the direct costs related to the issuance of the warrants were $57,531 were recorded in the consolidated statements of operations and comprehensive loss.
		(e)	In July 2013, the Company completed an underwritten public offering for gross proceeds of $3,075,000 at a price of $2.05 per unit. The Company sold units comprised of an aggregate of 1,500,000 common shares and warrants to purchase an additional 375,000 common shares. The warrants are exercisable for a term of five years and have an exercise price of $2.55 per common share. After placement agent fees and estimated offering expenses, the Company received net proceeds from the offering of approximately $2.5 million. The Company determined the fair value of the warrant liability at issuance to be $328,350 using the Black-Scholes Option Pricing Model (Note 14). The direct costs related to the issuance of the common shares were $467,989 and were recorded as an offset against shareholders’ deficiency and the direct costs related to the issuance of the warrants were $57,525 were recorded in the consolidated statements of operations and comprehensive loss.
		(f)	In November 2013, the Company entered into an equity distribution agreement with Roth Capital Partners, LLC (“Roth”), pursuant to which the Company may from time to time sell up to 5,305,484 of the Company’s common shares for up to an aggregate of $16.8 million (or such lesser amount as may be permitted under applicable securities laws and regulations) through at-the-market issuances on the NASDAQ or otherwise.  Under the equity distribution agreement, the Company may at its discretion, from time to time, offer and sell common shares through Roth or directly to Roth for resale.  Sales of common shares through Roth, if any, will be made at such time and at such price as are acceptable to the Company, from time to time, by means of ordinary brokers' transactions on the NASDAQ or otherwise at market prices prevailing at the time of sale or as determined by the Company.  The Company is not required to sell shares under the equity distribution agreement. The Company will pay Roth a commission, or allow a discount, of 2.75% of the gross proceeds that the Company received from any sales of common shares under the equity distribution agreement. The Company has also agreed to reimburse Roth for certain expenses relating to the offering.  The direct costs related to the facility were recorded as deferred offering costs as at November 30, 2013. No sales were made under the equity distribution agreement in the year ended November 30, 2013.

Note_11_Options

Note 11 - Options	12 Months Ended
	Nov. 30, 2013
Note 11 - Options [Line Items]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	13	Restricted share units
	Effective May 28, 2010, the Company’s shareholders approved a Restricted Share Unit (“RSU”) Plan for officers and employees of the Company and reserved a maximum of 330,000 common shares for issuance under the plan. The RSU Plan will form part of the incentive compensation arrangements available to officers and employees of the Company and its designated affiliates. An RSU is a unit equivalent in value to one common share of the Company. Upon vesting of the RSUs and the corresponding issuance of common shares to the participant, or on the forfeiture and cancellation of the RSUs, the RSUs credited to the participant’s account will be cancelled. No RSUs have been issued under the plan.
Options Held [Member]	'
Note 11 - Options [Line Items]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	11	Options
	All grants of options to employees after October 22, 2009 are made from the Employee Stock Option Plan (the “Employee Stock Option Plan”). The maximum number of common shares issuable under the Employee Stock Option Plan is limited to 10% of the issued and outstanding common shares of the Company from time to time, or 2,143,061 based on the number of issued and outstanding common shares as at November 30, 2013. As at November 30, 2013, 1,691,132 options are outstanding and there were 451,929 options available for grant under the Employee Stock Option Plan. Each option granted allows the holder to purchase one common share at an exercise price not less than the closing price of the Company's common shares on the Toronto Stock Exchange on the last trading day prior to the grant of the option. Options granted under these plans generally have a maximum term of 10 years and generally vest over a period of up to three years.
	In August 2004, the Board of Directors of IPC Ltd. approved a grant of 2,763,940 performance-based stock options, to two executives who were also the principal shareholders of IPC Ltd. The vesting of these options is contingent upon the achievement of certain performance milestones.  A total of 1,658,364 performance-based stock options have been vested as of November 30, 2013. These options were still outstanding as at November 30, 2013 and are scheduled to expire in September 2014.
	In the year ended November 30, 2013, 391,000 (2012 – 955,000) stock options to management, directors and employees were granted.
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option-Pricing Model, consistent with the provisions of ASC topic 718.
	Option pricing models require the use of subjective assumptions, changes in these assumptions can materially affect the fair value of the options.
	The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options that have an expected life than is more than four years. For options that have an expected life of less than four years the Company uses its own volatility.
	The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options.
	The risk-free rate assumed in valuing the options is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is Nil as the Company is not expected to pay dividends in the foreseeable future.
	The weighted average fair value of employee stock options granted was estimated using the following assumptions:
			November 30,				November 30,
			2013				2012
	Volatility			64	%			64.7	%
	Risk-free interest rate			0.01	%			0.08	%
	Expected life (in years)			7				10.00
	Dividend yield			-				-
	The weighted average grant date fair value per options granted		$	3.09			$	2.51
	Details of stock option transactions are as follows:
							30-Nov-13												30-Nov-12												30-Nov-11
			Number of				Weighted				Weighted				Number of				Weighted				Weighted				Number of				Weighted		Weighted
			options				average				average				options				average				average				options				average		average
							exercise				grant date								exercise				grant date								exercise		grant date
							price per				fair value								price per				fair value								price per		fair value
							share												share												share
							$				$								$				$								$		$
	Outstanding, beginning of period,			4,139,059				4.86				2.76				3,216,954				5.33				2.82				3,038,698				5.53		2.87
	Granted			391,000				1.81				1.05				955,000				3.27				2.51				328,000				3.51		1.84
	Exercised			(3,500	)			1.81				0.09				-				-				-				(25,000	)			3.73		1.55
	Forfeiture			(67,000	)			-				-				(32,862	)			-				-				(4,667	)			-		-
	Expired			(4,487	)			654.48				403.93				(33	)			69.74				53.82				(120,077	)			6.01		1.61
	Balance at end of period			4,455,072				3.97				2.21				4,139,059				4.86				2.76				3,216,954				5.33		2.82
	Options exercisable, end of year			3,321,830				4.09				2.41				2,286,589				5.94				3.55				1,585,816				7.11		4.03
	As of November 30, 2013, the exercise prices, weighted average remaining contractual life of outstanding options and weighted average grant date fair values were as follows:
																	Options outstanding												Options exercisable
	Exercise				Number				Weighted				Weighted				Weighted				Number				Weighted				Weighted
	price				outstanding				average				average				average				exercisable				average				average
									exercise				remaining				grant								exercise				grant
									price per				contract				due								price per				date
									share				life (years)				fair value								share				fair value
									$								$								$				$
		Under	2.5			-				-				-				-				-				-				-
	2.51	-	5			4,415,333				3.38				3.1				1.77				3,282,091				3.28				1.82
	5.01	-	7.5			-				-				-				-				-				-				-
	7.51	-	10			-				-				-				-				-				-				-
	10.01	-	100			35,702				39.75				3.87				31.19				35,702				39.75				31.19
	300	-	500			3,971				331.15				2.3				223.52				3,971				331.15				223.52
	500.01	-	1,000.00			33				770.13				1.29				493.31				33				770.13				493.31
	1,000.01	-	1,500.00			33				1,149.13				0.45				709.18				33				1,149.13				709.18
						4,455,072				3.97												3,321,830				4.09
	Total unrecognized compensation cost relating to the unvested performance-based stock options at November 30, 2013 is approximately $1,771,200 (2012 - $2,214,000). During the year ended November 30, 2013, a performance condition was met as the FDA approved an ANDA for a certain drug, resulting in the vesting of 276,394 performance-based stock options. As a result, a stock-based compensation expense of $442,800 relating to these stock options was recognized in research and development expense in the year ended November 30, 2013 (2012 - $Nil).
	For the year ended November 30, 2013, 3,500 options were exercised for a cash consideration of $5,965.  For the year ended November 30, 2012, no options were exercised and for the year ended November 30, 2011, 25,000 options were exercised for a cash consideration of $93,165.
	The following table summarizes the components of stock-based compensation expense.
			November 30,				November 30,				November 30,
			2013				2012				2011
	Research and development			837,206				1,505,061				601,423
	Selling, general and administrative			316,676				818,784				101,037
				1,153,882				2,323,845				702,460
	The Company has estimated its stock option forfeitures to be $Nil at November 30, 2013 (2012 - $Nil; 2011 - $7,302).

Note_12_Deferred_Share_Units

Note 12 - Deferred Share Units	12 Months Ended
	Nov. 30, 2013
Deferred Compensation Arrangements Disclosure [Abstract]	'
Deferred Compensation Arrangements Disclosure [Text Block]	'
	12	Deferred share units
	Effective May 28, 2010, the Company’s shareholders approved a Deferred Share Unit (“DSU”) Plan to grant DSUs to its non-management directors and reserved a maximum of 110,000 common shares for issuance under the plan. The DSU Plan permits certain non-management directors to defer receipt of all or a portion of their board fees until termination of the board service and to receive such fees in the form of common shares at that time. A DSU is a unit equivalent in value to one common share of the Company based on the trading price of the Company's common shares on the Toronto Stock Exchange.
	Upon termination of board service, the director will be able to redeem DSUs based upon the then market price of the Company's common shares on the date of redemption in exchange for any combination of cash or common shares as the Company may determine.
	During the year ended November 30, 2013, one non-management board member elected to receive director fees in the form of DSUs under the Company’s DSU Plan. As at November 30, 2013, 43,040 DSUs are outstanding and 66,960 DSUs are available for grant under the DSU Plan.
			30-Nov-13				30-Nov-12				30-Nov-11
				$	shares			$	shares			$	shares
	Additional paid in capital			39,547		20,591		36,727		12,199		33,101		10,250
	Accrued liability			9,181		2,325		9,688		4,611		6,569		2,050

Note_14_Warrants

Note 14 - Warrants	12 Months Ended
	Nov. 30, 2013
Warrants [Abstract]	'
Warrants [Text Block]	'
	14	Warrants
	All the warrants issued to date by the Company are denominated in U.S. dollars and IPC’s functional currency is Canadian dollars. Under U.S. GAAP, where the strike price of warrants is denominated in a currency other than an entity's functional currency the warrants would not be considered indexed to the entity’s own stock and would consequently be considered to be a derivative liability. The warrants, in specified situations, provide for certain compensation remedies to a holder if the Company fails to timely deliver the shares underlying the warrants in accordance with the warrant terms.
	In connection with the February 1, 2011 private offering, the Company issued 4,800,000 five year Series A common share purchase warrants to purchase one half of a share of common stock at an exercise price of $2.50 per whole share and 4,800,000 two year Series B common share purchase warrants to purchase one half of a share of common stock at an exercise price of $2.50 per whole share. The Company also issued to the placement agents 96,000 warrants to purchase a share of common stock at an exercise price of $3.125 per share.
	The  fair value of the Series A warrants of $7,214,366 and Series B warrants of $5,441,216 were initially estimated at February 1, 2011 using the Black-Scholes Option Pricing Model, using volatilities of 70% and 59%, risk free interest rates of 0.99% and 0.29%, expected lives of 5 and 2 years, and dividend yields in each case of Nil, respectively. The fair value of the placement agents’ warrants were initially estimated at February 1, 2011 as $229,005 using the Black-Scholes Option Pricing Model, using volatility of 67%, a risk free interest rate of 0.99%, an expected life of 3 years, and a dividend yield of Nil. These placement agent warrants were expensed and are included in financing expense.
	The holders of Series A common share purchase warrants and placement agents warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of shares for which warrants are exercised multiplied by the difference between market price of common share and the exercise price divided by the market price. Also under U.S. GAAP, warrants with the cashless exercise option satisfying the explicit net settlement criteria are considered a derivative liability.
	In the registered direct unit offering completed in March 2013, gross proceeds of $3,121,800 were received through the sale of the Company’s units comprised of common stock and warrants.
	The offering was the sale of 1,815,000 units at a price of $1.72 per unit, with each unit consisting of one share of common stock and a five year warrant to purchase 0.25 of a share of common stock at an exercise price of $2.10 per share (“March 2013 Warrants”).
	The  fair value of the March 2013 Warrants of $407,558 were initially estimated at closing using the Black-Scholes Option Pricing Model, using volatilities of 63%, risk free interest rates of 0.40%, expected life of 5 years, and dividend yield of Nil.
	In the underwritten public offering completed in July 2013, gross proceeds of $3,075,000 were received through the sale of the Company’s units comprised of common stock and warrants. The offering was the sale of 1,500,000 units at a price of $2.05 per unit, each unit consisting of one share of common stock and a five year warrant to purchase 0.25 of a share of common stock at an exercise price of $2.55 per share (“July 2013 Warrants”).
	The  fair value of the July 2013 Warrants of $328,350 were initially estimated at closing using the Black-Scholes Option Pricing Model, using volatilities of 62.4%, risk free interest rates of 0.58%, expected life of 5 years, and dividend yield of Nil.
	The following table provides information on the 6,360,300 warrants outstanding and exercisable as of November 30, 2013:
	Warrant		Exercise price			Number			Expiry		Shares issuable
						outstanding					upon exercise
	Placement Agent Warrants			3.125			96,000		30-Mar-14			96,000
	Series A Warrants			2.5			3,670,000		1-Feb-16			1,835,000
	March 2013 Warrants			2.1			1,724,300		22-Mar-18			431,075
	July 2013 Warrants			2.55			870,000		31-Jul-18			217,500
							6,360,300					2,579,575
	During the year ended November 30, 2013, there were cash exercises in respect of 770,700 warrants (2012 – 150,000) and no cashless exercise (2012 – 1,300,000) of warrants, resulting in the issuance of 205,175 (2012 – 75,000) and Nil (2012 – 105,315) common shares, respectively. The fair value of $980,382 (2012- $1,005,692) for these shares was recorded as a charge to capital stock.
	Details of warrant transactions are as follows:
			Series A			Series B				Placement			Mar-13			Jul-13			Total
			Warrants			Warrants				Agent Warrants			Warrants			Warrants
	Outstanding, December 1, 2012			3,720,000			3,470,000				96,000			-			-			7,286,000
	Issued			-			-				-			1,815,000			1,500,000			3,315,000
	Exercised			(50,000	)		-				-			(90,700	)		(630,000	)		(770,700	)
	Expired			-			(3,470,000	)			-			-			-			(3,470,000	)
	Outstanding, November 30, 2013			3,670,000			-				96,000			1,724,300			870,000			6,360,300
			Series A			Series B				Placement			7-May			Total
			Warrants			Warrants				Agent Warrants			Warrants
	Outstanding, December 1, 2011			4,695,000			3,945,000				96,000			243,275			8,979,275
	Issued			-			-				-			-			-
	Exercised			(975,000	)		(475,000	)			-			-			(1,450,000	)
	Expired			-			-				-			(243,275	)		(243,275	)
	Outstanding, November 30, 2012			3,720,000			3,470,000				96,000			-			7,286,000
	U.S. GAAP requires the fair value of these liabilities be re-measured at the end of every reporting period with the change in value reported in the consolidated statements of operations and comprehensive loss.
	Accordingly, using the Black-Scholes Option Pricing Model, the fair market value of the warrants are as follows:
	Warrants		30-Nov-13			30-Nov-12
			$			$
	Series B Warrants			-			276,038
	Placement Agent Warrants			112,550			25,363
	Series A Warrants			3,790,736			1,659,492
	March 2013 Warrants			1,040,788			-
	July 2013 Warrants			493,947			-
				5,438,021			1,960,893
	Using the following assumptions as of November 30, 2013 and 2012 respectively:
	Warrant		Number			Volatility				Risk-free			Expected
			outstanding							rate			life
						%				%			years
	Placement Agent Warrants			96,000			86.51				0.12			0.2
	Series A Warrants			3,670,000			67.93				0.12			2.2
	March 2013 Warrants			1,724,300			54.84				0.64			4.3
	July 2013 Warrants			870,000			55.51				0.64			4.7
	Warrant		Warrants			Volatility				Risk free			Expected
			outstanding							rate			life (years)
						%				%
	Series A			3,720,000			54.9				0.37	%		3.1
	Series B			3,470,000			48.2				0.18	%		0.2
	Placement Agent Warrants			96,000			46.15				0.18	%		1.1
	The change in the fair value of the warrants from the previously recorded amount to November 30, 2013 amounting to a loss of $3,356,534 (2012 – gain of $3,841,233: 2011 – gain of $5,346,878) has been recorded as a fair value adjustment of derivative liability in the consolidated statements of operations and comprehensive loss.

Note_15_Income_Taxes

Note 15 - Income Taxes	12 Months Ended
	Nov. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	15	Income taxes
	The Company files Canadian income tax returns for its Canadian operations. Separate income tax returns are filed as locally required.
	The total provision for income taxes differs from the amount which would be computed by applying the Canadian income tax rate to loss before income taxes. The reasons for these differences are as follows:
			November 30,			November 30,			November 30,
			2013			2012			2011
			%			%			%
	Statutory income tax rate			26.5			27			28
			$			$			$
	Statutory income tax recovery			(3,046,180	)		(1,632,406	)		(1,366,478	)
	Increase (decrease) in income taxes
	Non-deductible expenses/ non-taxable income			1,446,008			(399,748	)		(1,324,979	)
	Change in valuation allowance			1,248,045			3,217,198			2,452,926
	Investment tax credit			(164,308	)		(561,988	)		-
	Financing costs booked to equity			(307,262	)		-			-
	Ontario tax rate change			-			(420,990	)		-
	Foreign exchange change			746,667			(230,695	)		-
	True up of tax returns, etc.			77,030			28,629			238,531
				-			-			-
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities and certain carry-forward balances. Significant temporary differences and carry-forwards are as follows:
			November 30,			November 30,			November 30,
			2013			2012			2011
			$			$			$
	Deferred tax assets
	Non-capital loss carry-forwards			6,831,991			6,031,917			4,147,325
	Book and tax basis differences on assets and liabilities			992,378			773,590			824,640
	Other			37,136			17,590			8,635
	Ontario harmonization tax credit			399,831			427,355			361,888
	Investment tax credit			2,324,856			2,089,238			1,351,859
	Undeducted research and development expenditures			2,180,640			2,179,097			1,607,242
				12,766,832			11,518,787			8,301,589
	Valuation allowances for deferred tax assets			(12,766,832	)		(11,518,787	)		(8,301,589	)
	Net deferred tax assets			-			-			-
	At November 30, 2013, the Company had cumulative operating losses available to reduce future years’ income for income tax purposes:
	Canadian income tax losses expiring in the year ended November 30,		Federal
			$
	2013			(1,162,039	)
	2014			(2,129,847	)
	2025			(513,476	)
	2026			-
	2027			(1,372,624	)
	2028			(808,024	)
	2029			(597,768	)
	2030			(3,629,479	)
	2031			(4,938,324	)
	2032			(5,380,452	)
	2033			(5,165,818	)
				(25,697,851	)
	United States Federal income tax losses expiring in the year ended November 30,
				$
	2024			35,957
	2025			16,234
	2026			34,523
				86,714
	At November 30, 2013, the Company had a cumulative carry-forward pool of Federal SR&ED expenditures in the amount of approximately $10,310,000 (2012 - $9,822,000) which can be carried forward indefinitely.
	At November 30, 2013, the Company had approximately $400,000 (2012 - $427,000) of Ontario harmonization credits, which will expire in the November 30, 2014 taxation year. These credits are subject to a full valuation allowance as they are not more likely than not to be realized.
	At November 30, 2013, the Company had approximately $2,325,000 (November 30, 2012 - 2,089,000) of unclaimed ITCs which expire from 2025 to 2033. These credits are subject to a full valuation allowance as they are not more likely than not to be realized.
	The net deferred tax assets have been fully offset by a valuation allowance because it is not more likely than not the Company will realize the benefit of these deferred tax assets. The Company does not have any recognized tax benefits as of November 30, 2013 or November 30, 2012.
	The Company files unconsolidated federal income tax returns domestically and in foreign jurisdictions. The Company has open tax years from 2007 to 2013 with tax jurisdictions including Canada and the U.S. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations, as they relate to amount, timing, or inclusion of revenues and expenses.
	The Company did not incur any interest expense related to uncertain tax positions in 2013, 2012 and 2011 or any penalties in those years. The Company had no accrued interest and penalties as of November 30, 2013 and 2012.
	The Company had no unrecognized tax benefits in 2013, 2012 and 2011, and the Company does not expect that the unrecognized tax benefit will increase within the next twelve months.

Note_16_Contingencies

Note 16 - Contingencies	12 Months Ended
	Nov. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	16	Contingencies
	From time to time, the Company may be exposed to claims and legal actions in the normal course of business, including those which the Company may initiate.  The Company is not aware of any pending or threatened litigation claims outstanding.
	Pursuant to an arrangement agreement between Vasogen and Cervus LP (“Cervus”) dated August 14, 2009 (the "Cervus Agreement"), Vasogen and a Vasogen subsidiary (“New Vasogen”) entered into an indemnity agreement (the "Indemnity Agreement"), which became an obligation of the Company as of October 22, 2009. The Indemnity Agreement is designed to provide Cervus with indemnification for claims relating to Vasogen's and New Vasogen's business that are brought against Cervus in the future, subject to certain conditions and limitations. The Company's obligations under the Indemnity Agreement relating to the Tax pools defined in the Indemnity Agreement are limited to an aggregate of C$1,455,000 with a threshold amount of C$50,000 before there is an obligation to make a compensation payment. The Company does not presently expect to have to pay any amount under this indemnity agreement.

Note_17_Financial_Instruments

Note 17 - Financial Instruments	12 Months Ended
	Nov. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Financial Instruments Disclosure [Text Block]	'
	17.	Financial instruments
		(a)	Fair values
	The Company follows ASC topic 820, “Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC 820 apply to other accounting pronouncements that require or permit fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date; and establishes a three level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.
	Inputs refers broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of the hierarchy are defined as follows:
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for substantially the full term of the financial instrument.
	Level 3 inputs are unobservable inputs for asset or liabilities. There were no transfers in or out of Level 3 instruments during the year ended November 30, 2013.
	The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
	The following table presents for each of the fair value hierarchies, the assets and liabilities that are measured at fair value on a recurring basis as of November 30, 2013 and November 30, 2012:
											30-Nov-13
			Fair Value				Level 1				Level 2			Level 3
			$				$				$			$
	(a) Cash and cash equivalents			760,586				760,586				-			-
	(b) Convertible debt1			728,950				-				-			728,950
	(c) Warrant liabilities2			5,438,022				-				-			5,438,022
				6,927,558				760,586				-			6,166,972
											30-Nov-12
			Fair Value				Level 1				Level 2			Level 3
			$				$				$			$
	(a) Cash and cash equivalents			497,016				497,016				-			-
	(b) Warrant liabilities2			1,960,893				-				-			1,960,893
				2,457,909				497,016				-			1,960,893
	(1)  Conversion options are included in the convertible debenture on the consolidated balance sheet.
	(2)   Warrant liabilities are included on the consolidated balance sheet.
	The key unobservable inputs related to valuing the conversion option and warrant liabilities are as follows:
	Quantitative information about Level 3 Fair Value Measurements
			Fair value at			Valuation		Unobservable Input		Range
			30-Nov-13			Techniques
			$
	Conversion option			728,950		Black-Scholes		Discount rate				0.12%
								Volatility				64.60%
	Warrant liabilities			5,422,560		Black-Scholes		Discount rate			0.12%	-	0.64%
								comparable annualized volatility(i)			54%	-	87%
		(i)	The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options that have an expected life that is more than four years.
		(ii)	The Company calculates the interest rate for the conversion option based on the Company’s estimated cost of raising capital.
	An increase/decrease in the volatility and/or an decrease/increase in the discount rate would result in an increase/decrease in the fair value of the conversion option and warrant liabilities.
	The change in fair value of the conversion option and the warrant liabilities has been recorded as a fair value adjustment of derivative liabilities in the consolidated statements of operations and comprehensive loss.
	Reconciliation of Level 3 fair value measurements:
							30-Nov-13
			Conversion				Warrant				Total
			Option				liability
			$				$				$
	Opening balance			-				1,960,893				1,960,893
	Total gains or losses:
	- in net loss(a)			533,149				3,356,534				3,889,683
	- translation adjustment			(24,299	)			(449,224	)			(473,523	)
	Additions			220,100				735,908				956,008
	Exercise			-				(166,089	)			(166,089	)
	Closing balance			728,950				5,438,022				6,166,972
							30-Nov-12
			Conversion				Warrant				Total
			Option				liability
			$				$				$
	Opening balance			-				6,611,015				6,611,015
	Total gains or losses:											-
	- in net loss(a)			-				(3,841,233	)			(3,841,233	)
	- translation adjustment							(20,026	)			(20,026	)
	Additions			-				-				-
	Exercise			-				(788,863	)			(788,863	)
	Closing balance			-				1,960,893				1,960,893
		(a)	The total net loss related to the conversion option and warrant liability has been recorded under fair value adjustment derivative liabilities on the consolidated statements of operations and comprehensive loss.
	Fair value of financial assets and financial liabilities that are not measured at fair value on a recurring basis are as follows:
			30-Nov-13								30-Nov-12
		Carrying				Fair				Carrying			Fair
		amount				value				amount			value
		$				$				$			$
Financial Liabilities
Due to related parties(iii)			759,564				515,130				783,717			531,510
Convertible debt(iii)			1,376,456				1,290,683				-			-
	(iii)	The Company calculates the interest rate for the convertible debt and due to related parties based on the Company’s estimated cost of raising capital and uses the discounted cash flow model to calculate the fair value of the convertible debt and the amounts due to related parties.
The carrying values accounts receivable, and accounts payable, employee cost payable and capital lease obligations and approximates their fair values because of the short-term nature of these instruments.
	(b)	Interest rate and credit risk
Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates, relative to interest rates on cash and cash equivalents, due to related parties and capital lease obligations due to the short-term nature of these balances.
Trade accounts receivable potentially subjects the Company to credit risk. The Company provides an allowance for doubtful accounts equal to the estimated losses expected to be incurred in the collection of accounts receivable.
The following table sets forth details of the cash and cash equivalents:
		November 30,				November 30,
		2013				2012
		$				$
Cash			760,586				447,016
Bankers acceptance (30 days maturity, interest 0.10%)			-				50,000
Total cash and cash equivalents			760,586				497,016
The following table sets forth details of the aged accounts receivable that are not overdue as well as an analysis of overdue amounts and the related allowance for doubtful accounts:
		November 30,				November 30,
		2013				2012
		$				$
Total accounts receivable			1,475,745				2,778
Less allowance for doubtful accounts			-				-
Total accounts receivable, net			1,475,745				2,778
Not past due			1,473,097				2,778
Past due for more than 31 days but no more than 60 days			2,648				-
Total accounts receivable, net			1,475,745				2,778
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of uncollateralized accounts receivable. The Company’s maximum exposure to credit risk is equal to the potential amount of financial assets. For the year ended November 30, 2013, Par accounted for substantially all the revenue and all the accounts receivable of the Company. For the year ended November 30, 2012, Par accounted for all the revenue and all the accounts receivable of the Company. For the year ended November 30, 2011, Par accounted for substantially all the revenue and all the accounts receivable of the Company.
The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not subject to any external restrictions.
	(c)	Foreign exchange risk
The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 million, a +/- 10% movement in the Canadian currency held by the Company versus the US dollar would affect the Company’s loss and other comprehensive loss by $0.1 million.
Balances denominated in foreign currencies that are considered financial instruments are as follows:
		30-Nov-13								30-Nov-12
		Canadian				U.S				Canadian			U.S
FX rates used to translate to U.S.			1.062								0.9936
			$			$					$		$
Assets
Cash			461,002				434,089				247,397			248,991
			461,002				434,089				247,397			248,991
Liabilities
Accounts payable			484,299				456,025				284,727			286,561
Employee cost payable			182,970				172,288				189,383			190,603
Capital lease			45,947				43,265				51,194			51,524
Due to related party			806,657				759,564				778,701			783,716
			1,519,873				1,431,142				1,304,005			1,312,404
Net exposure			(1,058,871	)			(997,053	)			(1,056,608	)		(1,063,413	)
	(d)	Liquidity risk
Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown.
The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at November 30, 2013:
																30-Nov-13
		Less than				3 to 6				6 to 9			9 months			Greater than		Total
		3 months				months				months			1 year			1 year
		$				$				$			$			$		$
Third parties
Accounts payable			810,381				-				-			-			-		810,381
Capital lease			13,189				13,676				14,198			2,201			-		43,264
Related parties
Employee costs payable (Note 7)			508,616				-				-			-			-		508,616
Due to related parties (Note 6)			759,564				-				-			-			-		759,564
Convertible debenture (Note 6)			44,353				44,353				45,339			44,846			1,515,770		1,694,661
			2,136,103				58,029				59,537			47,047			1,515,770		3,816,486

Note_18_Segmented_Information

Note 18 - Segmented Information	12 Months Ended
	Nov. 30, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	18	Segmented information
	The Company's operations comprise a single reporting segment engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. As the operations comprise a single reporting segment, amounts disclosed in the financial statements for revenue, loss for the year, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in Canada.
			November 30,		November 30,		November 30,
			2013		2012		2011
			$		$		$
	Revenue
	United States			1,527,474		107,091		501,814
				1,527,474		107,091		501,814
	Total assets
	Canada			4,379,501		2,474,878		6,247,228
	Total property and equipment
	Canada			1,231,309		1,535,703		951,914

Note_19_Restatement_of_Compara

Note 19 - Restatement of Comparative Amounts	12 Months Ended
	Nov. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	19	Restatement of comparative amounts
	The Company previously classified the issuance of common shares as a credit to additional paid in capital. In accordance with U.S. GAAP, shares issued with no par value are required to be classified under capital stock. The adjustment is a reclassification from additional paid in capital into capital stock and has an immaterial impact on the consolidated statement of shareholder’s deficiency. Items previously reported have been reclassified to conform to U.S. GAAP and did not have any impact on the Company’s earnings per share calculations.
	The following table summarizes the impact of the restatement adjustments on the Company’s previously reported consolidated financial statements:
			As previously		Adjustment			As restated
			reported
			$		$			$
	Consolidated balance sheet and consolidated statements of shareholders' deficiency
	30-Nov-11
	Capital stock			147,152		755,124			902,276
	Additional paid in capital			20,822,672		(755,124	)		20,067,548
	30-Nov-12
	Capital stock			147,152		5,981,545			6,128,697
	Additional paid in capital			28,409,665		(5,981,545	)		22,428,120

Note_20_Subsequent_Events

Note 20 - Subsequent Events	12 Months Ended
	Nov. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	20	Subsequent events
	Subsequent to the year end, pursuant to the equity distribution agreement with Roth as disclosed in note 10, the Company sold through at-the-market issuances 1,312,100 of its common shares on the NASDAQ, for net proceeds of $4,808,054 to the Company and paid commission fees of $135,960 to Roth.  Share issuance costs of $419,777 were recorded against the cost of the shares issued and recognized in capital stock.  As at November 30, 2013, $419,777 of the share issuance costs have been deferred on the consolidated balance sheet.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Basis of consolidation
	These consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiaries, IPC Ltd., Intellipharmaceutics Corp. (“IPC Corp”), and Vasogen Corp. These consolidated financial statements also include the results of Vasogen Ireland Ltd. up to June 27, 2012, the date of its dissolution.
	All inter-company accounts and transactions have been eliminated on consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates
	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates.
	Areas where significant judgment is involved in making estimates are: the determination of estimated useful lives of property and equipment; the fair values of financial assets and liabilities; the determination of units of accounting for revenue recognition; the accrual of licensing and milestone revenue; the fair value of stock options and the determination of performance criteria for expensing stock-based payments; the fair value of warrants; the fair value of conversion option embedded derivative; evaluation of income tax positions; the determination of valuation allowances; the determination of investment tax credits; deferred revenue; forecasting future cash flows for assessing whether there are any impairments of long-lived assets; and the going concern assumption.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and cash equivalents
	The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. Cash equivalent balances consist of bankers’ acceptances and bank accounts with variable, market rates of interest.
	The financial risks associated with these instruments are minimal and the Company has not experienced any losses from investments in these securities. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
Receivables, Policy [Policy Text Block]	'
	Accounts receivable
	The Company reviews its sales and accounts receivable aging and determines whether an allowance for doubtful accounts is required.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Financial instruments
	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are classified as liabilities, the derivative instrument is initially recorded at its fair value using the appropriate valuation methodology and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss.
Regulatory Income Taxes, Policy [Policy Text Block]	'
	Investment tax credits
	The investment tax credits (“ITC") receivable are amounts considered recoverable from the Canadian federal and provincial governments under the Scientific Research & Experimental Development (“SR&ED”) incentive program. The amounts claimed under the program represent the amounts submitted by management based on research and development costs incurred during the year up to November 30, 2013. Realization is subject to government approval. Any adjustment to the amounts claimed will be recognized in the year in which the adjustment occurs. Refundable ITCs claimed relating to capital expenditures are credited to property and equipment. Refundable ITCs claimed relating to current expenditures are netted against research and development expenditures.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and equipment
	Property and equipment are recorded at cost. Equipment acquired under capital leases are recorded net of imputed interest, based upon the net present value of future payments. Assets under capital leases are pledged as collateral for the related lease obligation. Repairs and maintenance expenditures are charged to operations; major betterments and replacements are capitalized. Depreciation bases and rates are as follows:
	Assets	Basis	Rate
	Computer equipment	Declining balance	30%
	Computer software	Declining balance	50%
	Furniture and fixtures	Declining balance	20%
	Laboratory equipment	Declining balance	20%
	Leasehold improvements	Straight line	Over term of lease
	Leasehold improvements and assets acquired under capital leases are depreciated over the term of their useful lives or the lease period, whichever is shorter. The charge to operations resulting from depreciation of assets acquired under capital leases is included with depreciation expense.
Property, Plant and Equipment, Impairment [Policy Text Block]	'
	Impairment of long-lived assets
	Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on internal or external appraisals.
Warrants [Policy Text Block]	'
	Warrants
	The Company issued warrants as described in Notes 10 and 14.  The warrants are presented as a liability because they do not meet the criteria of Accounting Standard Codification (“ASC”) topic 480 for equity classification. Subsequent changes in the fair value of the warrants are recorded in the consolidated statements of operations and comprehensive loss.
Convertible Debt [Policy Text Block]	'
	Convertible debenture
	The Company issued a convertible debenture as described in Note 7.  The conversion option is bifurcated from its host contract and the fair value of the conversion option is characterized as an embedded derivative upon issuance as it meets the criteria of ASC Topic ASC815-15-25-1 Embedded Derivatives. Subsequent changes in the fair value of the embedded derivative are recorded in the consolidated statements of operations and comprehensive loss. The proceeds received from the Debenture less the initial amount allocated to the embedded derivative are allocated to the liability and are accreted over the life of the Debenture using the imputed rate of interest.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition
	The Company accounts for revenue in accordance with the provision of ASC topic 605 Revenue Recognition. The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing payments on sales of resulting products and other incidental services. Revenue is realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed or determinable, and collectability is reasonably assured. From time to time, the Company enters into transactions that represent multiple-element arrangements. Management evaluates arrangements with multiple deliverables to determine whether the deliverables represent one or more units of accounting for the purpose of revenue recognition.
	A delivered item is considered a separate unit of accounting if the delivered item has stand-alone value to the customer, the fair value of any undelivered items can be reliably determined, and the delivery of undelivered items is probable and substantially in the Company's control.
	The relevant revenue recognition accounting policy is applied to each separate unit of accounting.
	Licensing
	The Company recognizes license revenue from the licensing of the Company's drug delivery technologies, products and product candidates. Licensing revenue is recognized as earned in accordance with the contract terms when the amounts can be reasonably estimated and collectability is reasonably assured.
	The Company has a License and Commercialization Agreement with Par. Under the exclusive territorial license rights granted to Par, the agreement requires that Par manufacture, promote, market, sell and distribute the product. License revenue amounts receivable by the Company under this agreement are calculated and reported to the Company by Par, with such amounts generally based upon net product sales and net profit which include estimates for chargebacks, rebates, product returns, and other adjustments.  License revenue payments received by the Company from Par under this agreement are not subject to deductions for chargebacks, rebates, product returns, and other pricing adjustments.  Based on this arrangement and the guidance per ASC topic 605, the Company records license revenue as earned in the consolidated statements of operations and comprehensive loss.
	Milestones
	In connection with the License and Commercialization Agreement with Par, if the Company’s product is the only generic in the market or if there is only one generic competitor, a milestone payment is earned.  Revenue is recognized when the milestones are achieved. The milestone method recognizes revenue on substantive milestone payments in the period the milestone is achieved. Milestones are considered substantive if all of the following conditions are met: (i) the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) the milestone relates solely to past performance; and (iii) the milestone is reasonable relative to all of the deliverables and payment terms within the arrangement. Nonsubstantive milestone payments that might be paid to the Company based on the passage of time or as a result of a partner’s performance are allocated to the units of accounting within the arrangement; they are recognized as revenue in a manner similar to those units of accounting.
	Research and development
	Under arrangements where the license fees and research and development activities can be accounted for as a separate unit of accounting, non-refundable upfront license fees are deferred and recognized as revenue on a straight-line basis over the expected term of the Company's continued involvement in the research and development process.
	Deferred revenue represents the funds received from clients, for which the revenues have not yet been earned, as the milestones have not been achieved, or in the case of upfront fees for drug development, where the work remains to be completed.
	Other incidental services
	Incidental services which we may provide from time to time include, consulting advice provided to other organizations regarding FDA standards. Revenue is earned and realized when all of the following conditions are met:  (i) there is persuasive evidence of an arrangement; (ii) service has been rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and development costs
	Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. However, materials and equipment are capitalized and amortized over their useful lives if they have alternative future uses.
Income Tax, Policy [Policy Text Block]	'
	Income taxes
	The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for losses and tax credit carry forwards. Significant judgment is required in determining whether deferred tax assets will be realized in full or in part. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the year that includes the date of enactments. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized.
	The Company accounts in accordance with ASC topic 740-10. This ASC topic requires that uncertain tax positions are evaluated in a two-step process, whereby (i) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (ii) those tax positions that meet the more likely than not recognition threshold, the Company would recognize the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the related tax authority. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The cumulative effects of the application of the provisions of ASC topic 740-10 are described in Note 15.
	The Company records any interest related to income taxes in interest expense and penalties in selling, general and administrative expense.
Share Issue Costs [Policy Text Block]	'
	Share issue costs
	Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Share issue costs incurred in respect of issuing common shares in the at-the-market offering facility have been deferred and are recorded as deferred offering costs in 2013.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Translation of foreign currencies
	The consolidated financial statements of the Company are measured using the Canadian dollar as the functional currency. The Company's reporting currency is the U.S. dollar. The financial results of the Canadian operations are measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operations have been translated at year end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the consolidated financial statements of the Canadian operations are included as part of accumulated other comprehensive (loss) income, a separate component of shareholders' equity.
	In respect of other transactions denominated in currencies other than the respective entities' functional currencies, the monetary assets and liabilities are translated at the year end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the consolidated statements of operations and comprehensive loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based compensation
	The Company has a stock-based compensation plan which authorizes the granting of various equity-based incentives including stock options and restricted share units (“RSU”s). The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the expected life of the option. The provisions of the Company's stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity.
	Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation expense is recorded in the consolidated statements of operations and comprehensive loss under research and development expense and under selling, general and administration expense. Note 11 provides supplemental disclosure of the Company's stock options.
Deferred Share Units [Policy Text Block]	'
	Deferred Share Units
	Deferred Share Units (“DSU”s) are valued based on the trading price of the Company’s common shares on the Toronto Stock Exchange.  The Company records the value of the DSU’s owing to non-management board members in the consolidated statement of deficiency.
Earnings Per Share, Policy [Policy Text Block]	'
	Loss per share
	Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.
	The dilutive effect of stock options is determined using the treasury stock method. Stock options and warrants to purchase 7,034,647, 7,830,059 and 7,876,229 common shares of the Company during fiscal 2013, 2012, and 2011, respectively, were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended November 30, 2013, 2012 and 2011 as the effect would be anti-dilutive.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive loss
	The Company follows ASC topic 810-10. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity. Other than foreign exchange gains and losses arising from cumulative translation adjustments, the Company has no other comprehensive loss items.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair value measurement
	Under ASC topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy based on the reliability of inputs, as follows:
		●	Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
		●	Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.
		●	Level 3 - Unobservable inputs for the asset or liability.
	The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently adopted accounting pronouncements
	In February 2013, the FASB provided amendments to Accounting Standards Update (“ASU”) No. 2013-02 “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. Early adoption is permitted. The Company adopted the amendments on March 1, 2013. The adoption did not have an impact on the Company’s financial position, results of operations or cash flow.
Future Accounting Pronouncements [Policy Text Block]	'
	Future Accounting pronouncements
	In March 2013, the FASB provided amendments to ASU No. 2013-05 “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (a consensus of the FASB Emerging Issues Task Force)”. The amendments are effective prospectively for reporting periods beginning after December 15, 2013. The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations or cash flow.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for an net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. The ASU does not require new recurring disclosures. It is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption and retrospective application are permitted.  The Company does not expect the adoption of the amendments to have a material impact on the Company’s financial position, results of operations or cash flow.

Note_3_Significant_Accounting_1

Note 3 - Significant Accounting Policies (Tables)	12 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Depreciation Rates [Table Text Block]	'
	Assets	Basis	Rate
	Computer equipment	Declining balance	30%
	Computer software	Declining balance	50%
	Furniture and fixtures	Declining balance	20%
	Laboratory equipment	Declining balance	20%
	Leasehold improvements	Straight line	Over term of lease

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Nov. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		30-Nov-13
		Cost		Accumulated		Net book
				amortization		value
		$		$		$
	Computer equipment		228,854		177,831		51,023
	Computer software		113,862		79,603		34,259
	Furniture and fixtures		126,690		91,335		35,355
	Laboratory equipment		2,378,621		1,404,479		974,142
	Leasehold improvements		1,111,731		1,087,083		24,648
	Laboratory equipment under capital lease		202,584		100,138		102,446
	Computer equipment under capital lease		76,458		67,022		9,436
			4,238,800		3,007,491		1,231,309
		30-Nov-12
		Cost		Accumulated		Net book
				amortization		value
		$		$		$
	Computer equipment		243,798		188,935		54,863
	Computer software		126,568		53,916		72,652
	Furniture and fixtures		140,829		98,091		42,738
	Laboratory equipment		2,602,478		1,383,709		1,218,769
	Leasehold improvements		1,108,246		1,108,246		-
	Laboratory equipment under capital lease		225,192		88,617		136,575
	Computer equipment under capital lease		84,990		74,884		10,106
			4,532,101		2,996,398		1,535,703

Note_6_Accrued_Liabilities_Tab

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Nov. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		November 30,		November 30,
		2013		2012
		$		$
	Professional fees		468,986		116,179
	Other		200,335		108,618
			669,321		224,797

Note_7_Due_to_Related_Parties_

Note 7 - Due to Related Parties (Tables)	12 Months Ended
	Nov. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
		November 30,		November 30,
		2013		2012
		$		$
	Promissory note payable to two directors and officers of the Company, unsecured, 6% annual interest rate on the outstanding loan balance (i) (2013 - C$778,491; 2012 - C$750,534)		733,042		755,368
	Note payable to an entity controlled by shareholders, officers and directors of the Company, unsecured, non-interest bearing with no fixed repayment terms (2013 - C$28,167; 2012 - C$28,167)		26,522		28,349
			759,564		783,717
	Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly(ii)		2,105,406		-

Note_9_Lease_Obligations_Table

Note 9 - Lease Obligations (Tables)	12 Months Ended
	Nov. 30, 2013
Leases, Capital [Abstract]	'
Schedule of Future Minimum Lease Payments [Table Text Block]	'
	Year ending November 30,	Capital		Operating
		Lease		Lease
		$		$
	2014		46,079		84,356
			46,079		84,356
	Less: amounts representing interest at 14%		2,815		-
			43,264		84,356
	Less: current portion		43,264		84,356
	Balance, long-term portion		-		-

Note_11_Options_Tables

Note 11 - Options (Tables)	12 Months Ended
	Nov. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			November 30,				November 30,
			2013				2012
	Volatility			64	%			64.7	%
	Risk-free interest rate			0.01	%			0.08	%
	Expected life (in years)			7				10.00
	Dividend yield			-				-
	The weighted average grant date fair value per options granted		$	3.09			$	2.51
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
							30-Nov-13												30-Nov-12												30-Nov-11
			Number of				Weighted				Weighted				Number of				Weighted				Weighted				Number of				Weighted		Weighted
			options				average				average				options				average				average				options				average		average
							exercise				grant date								exercise				grant date								exercise		grant date
							price per				fair value								price per				fair value								price per		fair value
							share												share												share
							$				$								$				$								$		$
	Outstanding, beginning of period,			4,139,059				4.86				2.76				3,216,954				5.33				2.82				3,038,698				5.53		2.87
	Granted			391,000				1.81				1.05				955,000				3.27				2.51				328,000				3.51		1.84
	Exercised			(3,500	)			1.81				0.09				-				-				-				(25,000	)			3.73		1.55
	Forfeiture			(67,000	)			-				-				(32,862	)			-				-				(4,667	)			-		-
	Expired			(4,487	)			654.48				403.93				(33	)			69.74				53.82				(120,077	)			6.01		1.61
	Balance at end of period			4,455,072				3.97				2.21				4,139,059				4.86				2.76				3,216,954				5.33		2.82
	Options exercisable, end of year			3,321,830				4.09				2.41				2,286,589				5.94				3.55				1,585,816				7.11		4.03
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
																	Options outstanding												Options exercisable
	Exercise				Number				Weighted				Weighted				Weighted				Number				Weighted				Weighted
	price				outstanding				average				average				average				exercisable				average				average
									exercise				remaining				grant								exercise				grant
									price per				contract				due								price per				date
									share				life (years)				fair value								share				fair value
									$								$								$				$
		Under	2.5			-				-				-				-				-				-				-
	2.51	-	5			4,415,333				3.38				3.1				1.77				3,282,091				3.28				1.82
	5.01	-	7.5			-				-				-				-				-				-				-
	7.51	-	10			-				-				-				-				-				-				-
	10.01	-	100			35,702				39.75				3.87				31.19				35,702				39.75				31.19
	300	-	500			3,971				331.15				2.3				223.52				3,971				331.15				223.52
	500.01	-	1,000.00			33				770.13				1.29				493.31				33				770.13				493.31
	1,000.01	-	1,500.00			33				1,149.13				0.45				709.18				33				1,149.13				709.18
						4,455,072				3.97												3,321,830				4.09
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
			November 30,				November 30,				November 30,
			2013				2012				2011
	Research and development			837,206				1,505,061				601,423
	Selling, general and administrative			316,676				818,784				101,037
				1,153,882				2,323,845				702,460

Note_12_Deferred_Share_Units_T

Note 12 - Deferred Share Units (Tables)	12 Months Ended
	Nov. 30, 2013
Deferred Compensation Arrangements Disclosure [Abstract]	'
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
		30-Nov-13				30-Nov-12				30-Nov-11
			$	shares			$	shares			$	shares
	Additional paid in capital		39,547		20,591		36,727		12,199		33,101		10,250
	Accrued liability		9,181		2,325		9,688		4,611		6,569		2,050

Note_14_Warrants_Tables

Note 14 - Warrants (Tables)	12 Months Ended
	Nov. 30, 2013
Warrants [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'Warrants Outstanding and Exercisable
	Warrant	Exercise price			Number			Expiry		Shares issuable
					outstanding					upon exercise
	Placement Agent Warrants		3.125			96,000		30-Mar-14			96,000
	Series A Warrants		2.5			3,670,000		1-Feb-16			1,835,000
	March 2013 Warrants		2.1			1,724,300		22-Mar-18			431,075
	July 2013 Warrants		2.55			870,000		31-Jul-18			217,500
						6,360,300					2,579,575
	'
		Series A			Series B				Placement			Mar-13			Jul-13			Total
		Warrants			Warrants				Agent Warrants			Warrants			Warrants
	Outstanding, December 1, 2012		3,720,000			3,470,000				96,000			-			-			7,286,000
	Issued		-			-				-			1,815,000			1,500,000			3,315,000
	Exercised		(50,000	)		-				-			(90,700	)		(630,000	)		(770,700	)
	Expired		-			(3,470,000	)			-			-			-			(3,470,000	)
	Outstanding, November 30, 2013		3,670,000			-				96,000			1,724,300			870,000			6,360,300
		Series A			Series B				Placement			7-May			Total
		Warrants			Warrants				Agent Warrants			Warrants
	Outstanding, December 1, 2011		4,695,000			3,945,000				96,000			243,275			8,979,275
	Issued		-			-				-			-			-
	Exercised		(975,000	)		(475,000	)			-			-			(1,450,000	)
	Expired		-			-				-			(243,275	)		(243,275	)
	Outstanding, November 30, 2012		3,720,000			3,470,000				96,000			-			7,286,000
Schedule Of Fair Market Value Of Warrants [Table Text Block]	'
	Warrants	30-Nov-13			30-Nov-12
		$			$
	Series B Warrants		-			276,038
	Placement Agent Warrants		112,550			25,363
	Series A Warrants		3,790,736			1,659,492
	March 2013 Warrants		1,040,788			-
	July 2013 Warrants		493,947			-
			5,438,021			1,960,893
Schedule of Fair Value Assumptions for Warrants [Table Text Block]	'
	Warrant	Number			Volatility				Risk-free			Expected
		outstanding							rate			life
					%				%			years
	Placement Agent Warrants		96,000			86.51				0.12			0.2
	Series A Warrants		3,670,000			67.93				0.12			2.2
	March 2013 Warrants		1,724,300			54.84				0.64			4.3
	July 2013 Warrants		870,000			55.51				0.64			4.7
	Warrant	Warrants			Volatility				Risk free			Expected
		outstanding							rate			life (years)
					%				%
	Series A		3,720,000			54.9				0.37	%		3.1
	Series B		3,470,000			48.2				0.18	%		0.2
	Placement Agent Warrants		96,000			46.15				0.18	%		1.1

Note_15_Income_Taxes_Tables

Note 15 - Income Taxes (Tables)	12 Months Ended
	Nov. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		November 30,			November 30,			November 30,
		2013			2012			2011
		%			%			%
	Statutory income tax rate		26.5			27			28
		$			$			$
	Statutory income tax recovery		(3,046,180	)		(1,632,406	)		(1,366,478	)
	Increase (decrease) in income taxes
	Non-deductible expenses/ non-taxable income		1,446,008			(399,748	)		(1,324,979	)
	Change in valuation allowance		1,248,045			3,217,198			2,452,926
	Investment tax credit		(164,308	)		(561,988	)		-
	Financing costs booked to equity		(307,262	)		-			-
	Ontario tax rate change		-			(420,990	)		-
	Foreign exchange change		746,667			(230,695	)		-
	True up of tax returns, etc.		77,030			28,629			238,531
			-			-			-
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		November 30,			November 30,			November 30,
		2013			2012			2011
		$			$			$
	Deferred tax assets
	Non-capital loss carry-forwards		6,831,991			6,031,917			4,147,325
	Book and tax basis differences on assets and liabilities		992,378			773,590			824,640
	Other		37,136			17,590			8,635
	Ontario harmonization tax credit		399,831			427,355			361,888
	Investment tax credit		2,324,856			2,089,238			1,351,859
	Undeducted research and development expenditures		2,180,640			2,179,097			1,607,242
			12,766,832			11,518,787			8,301,589
	Valuation allowances for deferred tax assets		(12,766,832	)		(11,518,787	)		(8,301,589	)
	Net deferred tax assets		-			-			-
Schedule of Operating Losses [Table Text Block]	'
	Canadian income tax losses expiring in the year ended November 30,	Federal
		$
	2013		(1,162,039	)
	2014		(2,129,847	)
	2025		(513,476	)
	2026		-
	2027		(1,372,624	)
	2028		(808,024	)
	2029		(597,768	)
	2030		(3,629,479	)
	2031		(4,938,324	)
	2032		(5,380,452	)
	2033		(5,165,818	)
			(25,697,851	)
	United States Federal income tax losses expiring in the year ended November 30,
			$
	2024		35,957
	2025		16,234
	2026		34,523
			86,714

Note_17_Financial_Instruments_

Note 17 - Financial Instruments (Tables)	12 Months Ended
	Nov. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
										30-Nov-13
		Fair Value				Level 1				Level 2			Level 3
		$				$				$			$
	(a) Cash and cash equivalents		760,586				760,586				-			-
	(b) Convertible debt1		728,950				-				-			728,950
	(c) Warrant liabilities2		5,438,022				-				-			5,438,022
			6,927,558				760,586				-			6,166,972
										30-Nov-12
		Fair Value				Level 1				Level 2			Level 3
		$				$				$			$
	(a) Cash and cash equivalents		497,016				497,016				-			-
	(b) Warrant liabilities2		1,960,893				-				-			1,960,893
			2,457,909				497,016				-			1,960,893
Fair Value Inputs, Assets, Quantitative Information [Table Text Block]	'
	Quantitative information about Level 3 Fair Value Measurements
		Fair value at			Valuation		Unobservable Input		Range
		30-Nov-13			Techniques
		$
	Conversion option		728,950		Black-Scholes		Discount rate				0.12%
							Volatility				64.60%
	Warrant liabilities		5,422,560		Black-Scholes		Discount rate			0.12%	-	0.64%
							comparable annualized volatility(i)			54%	-	87%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
						30-Nov-13
		Conversion				Warrant				Total
		Option				liability
		$				$				$
	Opening balance		-				1,960,893				1,960,893
	Total gains or losses:
	- in net loss(a)		533,149				3,356,534				3,889,683
	- translation adjustment		(24,299	)			(449,224	)			(473,523	)
	Additions		220,100				735,908				956,008
	Exercise		-				(166,089	)			(166,089	)
	Closing balance		728,950				5,438,022				6,166,972
						30-Nov-12
		Conversion				Warrant				Total
		Option				liability
		$				$				$
	Opening balance		-				6,611,015				6,611,015
	Total gains or losses:										-
	- in net loss(a)		-				(3,841,233	)			(3,841,233	)
	- translation adjustment						(20,026	)			(20,026	)
	Additions		-				-				-
	Exercise		-				(788,863	)			(788,863	)
	Closing balance		-				1,960,893				1,960,893
Fair Value Measurements, Nonrecurring [Table Text Block]	'
		30-Nov-13								30-Nov-12
		Carrying				Fair				Carrying			Fair
		amount				value				amount			value
		$				$				$			$
	Financial Liabilities
	Due to related parties(iii)		759,564				515,130				783,717			531,510
	Convertible debt(iii)		1,376,456				1,290,683				-			-
Schedule of Cash and Cash Equivalents [Table Text Block]	'
		November 30,				November 30,
		2013				2012
		$				$
	Cash		760,586				447,016
	Bankers acceptance (30 days maturity, interest 0.10%)		-				50,000
	Total cash and cash equivalents		760,586				497,016
Past Due Financing Receivables [Table Text Block]	'
		November 30,				November 30,
		2013				2012
		$				$
	Total accounts receivable		1,475,745				2,778
	Less allowance for doubtful accounts		-				-
	Total accounts receivable, net		1,475,745				2,778
	Not past due		1,473,097				2,778
	Past due for more than 31 days but no more than 60 days		2,648				-
	Total accounts receivable, net		1,475,745				2,778
Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]	'
		30-Nov-13								30-Nov-12
		Canadian				U.S				Canadian			U.S
	FX rates used to translate to U.S.		1.062								0.9936
			$			$					$		$
	Assets
	Cash		461,002				434,089				247,397			248,991
			461,002				434,089				247,397			248,991
	Liabilities
	Accounts payable		484,299				456,025				284,727			286,561
	Employee cost payable		182,970				172,288				189,383			190,603
	Capital lease		45,947				43,265				51,194			51,524
	Due to related party		806,657				759,564				778,701			783,716
			1,519,873				1,431,142				1,304,005			1,312,404
	Net exposure		(1,058,871	)			(997,053	)			(1,056,608	)		(1,063,413	)
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	'
																30-Nov-13
		Less than				3 to 6				6 to 9			9 months			Greater than		Total
		3 months				months				months			1 year			1 year
		$				$				$			$			$		$
	Third parties
	Accounts payable		810,381				-				-			-			-		810,381
	Capital lease		13,189				13,676				14,198			2,201			-		43,264
	Related parties
	Employee costs payable (Note 7)		508,616				-				-			-			-		508,616
	Due to related parties (Note 6)		759,564				-				-			-			-		759,564
	Convertible debenture (Note 6)		44,353				44,353				45,339			44,846			1,515,770		1,694,661
			2,136,103				58,029				59,537			47,047			1,515,770		3,816,486

Note_18_Segmented_Information_

Note 18 - Segmented Information (Tables)	12 Months Ended
	Nov. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	'
		November 30,		November 30,		November 30,
		2013		2012		2011
		$		$		$
	Revenue
	United States		1,527,474		107,091		501,814
			1,527,474		107,091		501,814
	Total assets
	Canada		4,379,501		2,474,878		6,247,228
	Total property and equipment
	Canada		1,231,309		1,535,703		951,914

Note_19_Restatement_of_Compara1

Note 19 - Restatement of Comparative Amounts (Tables)	12 Months Ended
	Nov. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	'
		As previously		Adjustment			As restated
		reported
		$		$			$
	Consolidated balance sheet and consolidated statements of shareholders' deficiency
	30-Nov-11
	Capital stock		147,152		755,124			902,276
	Additional paid in capital		20,822,672		(755,124	)		20,067,548
	30-Nov-12
	Capital stock		147,152		5,981,545			6,128,697
	Additional paid in capital		28,409,665		(5,981,545	)		22,428,120

Note_1_Nature_of_Operations_De

Note 1 - Nature of Operations (Details) (USD $)	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Disclosure Text Block [Abstract]	'	'	'
Retained Earnings (Accumulated Deficit)	($41,579,701)	($30,084,684)	($23,947,819)

Note_3_Significant_Accounting_2

Note 3 - Significant Accounting Policies (Details)	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Accounting Policies [Abstract]	'	'	'
Options and Warrants Outstanding	7,034,647	7,830,059	7,876,229

Note_3_Significant_Accounting_3

Note 3 - Significant Accounting Policies (Details) - Depreciation Rates	12 Months Ended
	Nov. 30, 2013
Computer Equipment [Member] | Declining Balance [Member]	'
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]	'
Depreciation Rate	30.00%
Computer Software, Intangible Asset [Member] | Declining Balance [Member]	'
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]	'
Depreciation Rate	50.00%
Furniture and Fixtures [Member] | Declining Balance [Member]	'
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]	'
Depreciation Rate	20.00%
Laboratory Equipment [Member] | Declining Balance [Member]	'
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]	'
Depreciation Rate	20.00%
Leasehold Improvements [Member] | Straight Line [Member]	'
Note 3 - Significant Accounting Policies (Details) - Depreciation Rates [Line Items]	'
Leasehold improvements	'Over term of lease

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment (Details) (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Property, Plant and Equipment [Abstract]	'	'	'
Depreciation	$396,814	$452,303	$227,456
Asset Impairment Charges	'	$107,123	'

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment (Details) - Property and Equipment (USD $)	Nov. 30, 2013	Nov. 30, 2012
Property, Plant and Equipment [Line Items]	'	'
Cost	$4,238,800	$4,532,101
Accumulated amortization	3,007,491	2,996,398
Net book value	1,231,309	1,535,703
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	228,854	243,798
Accumulated amortization	177,831	188,935
Net book value	51,023	54,863
Computer Software, Intangible Asset [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	113,862	126,568
Accumulated amortization	79,603	53,916
Net book value	34,259	72,652
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	126,690	140,829
Accumulated amortization	91,335	98,091
Net book value	35,355	42,738
Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	2,378,621	2,602,478
Accumulated amortization	1,404,479	1,383,709
Net book value	974,142	1,218,769
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	1,111,731	1,108,246
Accumulated amortization	1,087,083	1,108,246
Net book value	24,648	'
Laboratory Equipment Under Capital Lease [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	202,584	225,192
Accumulated amortization	100,138	88,617
Net book value	102,446	136,575
Computer Equipment Under Capital Lease [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	76,458	84,990
Accumulated amortization	67,022	74,884
Net book value	$9,436	$10,106

Note_6_Accrued_Liabilities_Det

Note 6 - Accrued Liabilities (Details) - Accrued Liabilities (USD $)	Nov. 30, 2013	Nov. 30, 2012
Accrued Liabilities [Abstract]	'	'
Professional fees	$468,986	$116,179
Other	200,335	108,618
	$669,321	$224,797

Note_7_Due_to_Related_Parties_1

Note 7 - Due to Related Parties (Details)

0 Months Ended

1 Months Ended

12 Months Ended

Jan. 10, 2013

Nov. 30, 2013

Jul. 31, 2013

Mar. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

USD ($)

USD ($)

USD ($)

CAD

USD ($)

USD ($)

Coupon Interest Member

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

USD ($)

USD ($)

CAD

USD ($)

USD ($)

Note 7 - Due to Related Parties (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments from Net Cash (in Dollars)

'

'

'

'

'

800,000

'

'

'

'

'

'

'

Related Party Transaction, Amounts of Transaction

'

'

'

'

'

'

'

801,551

'

16,640

17,671

39,173

163,099

Related Party Transaction, Amounts of Transaction (in Dollars)

'

'

'

'

'

'

'

801,551

'

16,640

17,671

39,173

163,099

Interest Expense, Related Party

'

'

'

'

43,538

'

45,278

73,011

'

'

'

'

'

Debt Instrument, Face Amount

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Number of Equity Instruments

500,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$3

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt

1,500,000

'

'

'

1,500,000

'

'

'

'

'

'

'

'

Embedded Derivative, Fair Value of Embedded Derivative Liability

220,100

728,950

'

'

728,950

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

46.60%

64.60%

62.40%

63.00%

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

0.26%

0.12%

0.58%

0.40%

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'2 years

'1 year 36 days

'5 years

'5 years

'4 years

'4 years

'

'

'

'

'

'

'

Embedded Derivative, Gain (Loss) on Embedded Derivative, Net

'

-533,149

'

'

-533,149

[1]

'

'

[1]

'

'

'

'

'

'

Accretion Expense

'

1,279,900

'

'

'

'

'

'

'

'

'

'

'

Accretion Expense Imputed Interest Rate

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Debt

'

'

'

'

$96,556

'

'

'

$159,671

'

'

'

'

[1]

The total net loss related to the conversion option and warrant liability has been recorded under fair value adjustment derivative liabilities on the consolidated statements of operations and comprehensive loss.

Note_7_Due_to_Related_Parties_2

Note 7 - Due to Related Parties (Details) - Amounts Due to Related Parties

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

USD ($)

USD ($)

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Unsecured Convertible Debentures [Member]

Unsecured Convertible Debentures [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

USD ($)

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Note payable related party

$759,564

$783,717

$733,042

[1]

778,491

$755,368

[1]

750,534

$26,522

28,167

$28,349

28,167

'

'

Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly(ii)

'

'

'

'

'

'

'

'

'

'

$2,105,406

[2]

'

[2]

[1]

Promissory note payableThe promissory note dated September 10, 2004 issued by IPC Corp to Dr. Isa Odidi and Dr. Amina Odidi (the "Promissory Note"), principal shareholders, directors and executive officers of the Company was amended effective October 22, 2009 ("effective date"), to provide that the principal amount thereof shall be payable when payment is required solely out of (i) revenues earned by IPC Corp following the effective date, and/or proceeds received by any IPC Company from any offering of its securities following the effective date, other than the proceeds from the transactions completed in February 2011, March 2012, March 2013 and July 2013 (Note 10) and/or amounts received by IPC Corp for scientific research tax credits of IPC Corp and (ii) up to C$800,000 from the Net Cash (as defined in the IPC Arrangement Agreement). During the year ended November 30, 2013, no principal repayment was made (2012 - $Nil; 2011 -$801,551) and interest payment of $16,640 (C$17,671) (2012 - $39,173; 2011 - $163,099) in respect of the promissory note was made by the Company in accordance with the terms of the IPC Arrangement Agreement.Interest expense on the promissory note payable to related parties for the year ended November 30, 2013 is $43,538 (2012 - $45,278; 2011 - $73,011) and has been included in the consolidated statement of operations and comprehensive loss.

[2]

Convertible debentureOn January 10, 2013, the Company completed a private placement financing (the "Financing") of an unsecured convertible debenture in the principal amount of $1.5 million (the "Debenture"), which will mature January 1, 2015. The Debenture bears interest at a rate of 12% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into 500,000 common shares at a conversion price of $3.00 per common share at the option of the holder.Dr. Isa Odidi and Dr. Amina Odidi, principal shareholders, directors and executive officers of the Company purchased the Debenture and provided the Company with the $1.5 million of the proceeds for the Debenture.The conversion price of the Debenture is in U.S. dollars and IPC's functional currency is Canadian dollars. Under U.S. GAAP where the conversion price of the Debenture is denominated in a currency other than an entity's functional currency, the conversion option meets the definition of an embedded derivative. The conversion option is bifurcated from its host contract and the fair value of the conversion option characterized as an embedded derivative upon issuance. The embedded derivative is presented together on a combined basis with the host contract. The derivative is re-measured at the end of every reporting period with the change in value reported in the consolidated statements of operations and comprehensive loss.The proceeds received from the Debenture less the initial amount allocated to the embedded derivative were allocated to the liability and are accreted over the life of the Debenture using the imputed rate of interest. The fair value of the conversion option at January 10, 2013 using the Black-Scholes Option Pricing Model were initially estimated to be $220,100, using volatility of 46.6%, risk-free interest rate of 0.26%, expected life of two years, and dividend yield of Nil. The fair value of the conversion option at November 30, 2013 using the Black-Scholes Option Pricing Model was estimated to be $728,950, using volatility of 64.6%, risk-free interest rate of 0.12%, expected life of 1.1 years, and dividend yield of Nil. This amount has been recorded in the convertible debenture line on the consolidated balance sheet. The change in fair value of the conversion option from the previously recorded amount to the year ended November 30, 2013 is a loss of $533,149 (2012 - $Nil; 2011 - $Nil), and has been recorded as a fair value adjustment of derivative liabilities in the consolidated statements of operations and comprehensive loss. The proceeds of $1.5 million less the initial fair value of the conversion option embedded derivative of $220,100, totaled $1,279,900 and is accreted at an annual imputed interest rate of 8%, over the life of the Debenture. Accreted interest expense during year ended November 30, 2013 is $96,556 (2012 - $Nil; 2011 -$Nil), and has been included in the consolidated statements of operations and comprehensive loss. In addition, the coupon interest on the Debenture for the year ended November 30, 2013 is $159,671 (2012 - $Nil; 2011 - $Nil), and has also been included in the consolidated statements of operations and comprehensive loss.

Note_7_Due_to_Related_Parties_3

Note 7 - Due to Related Parties (Details) - Amounts Due to Related Parties (Parentheticals)

Nov. 30, 2013

Jan. 10, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

USD ($)

USD ($)

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Promissory Note Payable to Two Directors and Officers of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Note Payable to an Entity Controlled by Shareholders, Officers and Directors of the Company [Member]

Unsecured Convertible Debentures [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Note payable related party (Canadian Dollars)

$759,564

'

$783,717

$733,042

[1]

778,491

$755,368

[1]

750,534

$26,522

28,167

$28,349

28,167

'

Annual interest rate

'

12.00%

'

6.00%

[1]

6.00%

[1]

6.00%

[1]

6.00%

[1]

'

'

'

'

12.00%

[2]

[1]

Promissory note payableThe promissory note dated September 10, 2004 issued by IPC Corp to Dr. Isa Odidi and Dr. Amina Odidi (the "Promissory Note"), principal shareholders, directors and executive officers of the Company was amended effective October 22, 2009 ("effective date"), to provide that the principal amount thereof shall be payable when payment is required solely out of (i) revenues earned by IPC Corp following the effective date, and/or proceeds received by any IPC Company from any offering of its securities following the effective date, other than the proceeds from the transactions completed in February 2011, March 2012, March 2013 and July 2013 (Note 10) and/or amounts received by IPC Corp for scientific research tax credits of IPC Corp and (ii) up to C$800,000 from the Net Cash (as defined in the IPC Arrangement Agreement). During the year ended November 30, 2013, no principal repayment was made (2012 - $Nil; 2011 -$801,551) and interest payment of $16,640 (C$17,671) (2012 - $39,173; 2011 - $163,099) in respect of the promissory note was made by the Company in accordance with the terms of the IPC Arrangement Agreement.Interest expense on the promissory note payable to related parties for the year ended November 30, 2013 is $43,538 (2012 - $45,278; 2011 - $73,011) and has been included in the consolidated statement of operations and comprehensive loss.

[2]

Convertible debentureOn January 10, 2013, the Company completed a private placement financing (the "Financing") of an unsecured convertible debenture in the principal amount of $1.5 million (the "Debenture"), which will mature January 1, 2015. The Debenture bears interest at a rate of 12% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into 500,000 common shares at a conversion price of $3.00 per common share at the option of the holder.Dr. Isa Odidi and Dr. Amina Odidi, principal shareholders, directors and executive officers of the Company purchased the Debenture and provided the Company with the $1.5 million of the proceeds for the Debenture.The conversion price of the Debenture is in U.S. dollars and IPC's functional currency is Canadian dollars. Under U.S. GAAP where the conversion price of the Debenture is denominated in a currency other than an entity's functional currency, the conversion option meets the definition of an embedded derivative. The conversion option is bifurcated from its host contract and the fair value of the conversion option characterized as an embedded derivative upon issuance. The embedded derivative is presented together on a combined basis with the host contract. The derivative is re-measured at the end of every reporting period with the change in value reported in the consolidated statements of operations and comprehensive loss.The proceeds received from the Debenture less the initial amount allocated to the embedded derivative were allocated to the liability and are accreted over the life of the Debenture using the imputed rate of interest. The fair value of the conversion option at January 10, 2013 using the Black-Scholes Option Pricing Model were initially estimated to be $220,100, using volatility of 46.6%, risk-free interest rate of 0.26%, expected life of two years, and dividend yield of Nil. The fair value of the conversion option at November 30, 2013 using the Black-Scholes Option Pricing Model was estimated to be $728,950, using volatility of 64.6%, risk-free interest rate of 0.12%, expected life of 1.1 years, and dividend yield of Nil. This amount has been recorded in the convertible debenture line on the consolidated balance sheet. The change in fair value of the conversion option from the previously recorded amount to the year ended November 30, 2013 is a loss of $533,149 (2012 - $Nil; 2011 - $Nil), and has been recorded as a fair value adjustment of derivative liabilities in the consolidated statements of operations and comprehensive loss. The proceeds of $1.5 million less the initial fair value of the conversion option embedded derivative of $220,100, totaled $1,279,900 and is accreted at an annual imputed interest rate of 8%, over the life of the Debenture. Accreted interest expense during year ended November 30, 2013 is $96,556 (2012 - $Nil; 2011 -$Nil), and has been included in the consolidated statements of operations and comprehensive loss. In addition, the coupon interest on the Debenture for the year ended November 30, 2013 is $159,671 (2012 - $Nil; 2011 - $Nil), and has also been included in the consolidated statements of operations and comprehensive loss.

Note_8_Employee_Costs_Payable_

Note 8 - Employee Costs Payable (Details) (USD $)	Nov. 30, 2013	Nov. 30, 2012
Note 8 - Employee Costs Payable (Details) [Line Items]	'	'
Employee-related Liabilities, Current	$508,616	$663,222
Principal Shareholders, Directors, and Executive Officers [Member]	'	'
Note 8 - Employee Costs Payable (Details) [Line Items]	'	'
Employee-related Liabilities, Current	336,327	472,619
Certain Employees [Member]	'	'
Note 8 - Employee Costs Payable (Details) [Line Items]	'	'
Employee-related Liabilities, Current	$172,289	$190,603

Note_9_Lease_Obligations_Detai

Note 9 - Lease Obligations (Details) - Minimum Lease Payments (USD $)	Nov. 30, 2013	Nov. 30, 2012
Minimum Lease Payments [Abstract]	'	'
2014	$46,079	'
2014	84,356	'
	46,079	'
	84,356	'
Less: amounts representing interest at 14%	2,815	'
	43,264	'
	84,356	'
Less: current portion	43,264	51,524
Less: current portion	$84,356	'

Note_9_Lease_Obligations_Detai1

Note 9 - Lease Obligations (Details) - Minimum Lease Payments (Parentheticals)	Nov. 30, 2013
Minimum Lease Payments [Abstract]	'
Interest rate	14.00%

Note_10_Capital_Stock_Details

Note 10 - Capital Stock (Details) (USD $)

1 Months Ended

2 Months Ended

12 Months Ended

13 Months Ended

Nov. 30, 2013

Jul. 31, 2013

Mar. 31, 2013

Mar. 31, 2012

Jan. 31, 2011

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

Feb. 01, 2011

Mar. 31, 2013

Nov. 30, 2013

Nov. 30, 2012

Jan. 31, 2011

Feb. 01, 2011

Feb. 01, 2011

Common Stock [Member]

Odidi Holdco [Member]

Odidi Holdco [Member]

Private Placement Offering [Member]

Series A Common Share Purchase Warrant [Member]

Series B Common Share Purchase Warrant [Member]

Note 10 - Capital Stock (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued (in Shares)

21,430,611

'

'

'

'

21,430,611

17,906,937

'

'

'

5,997,751

6,005,751

'

'

'

Common Stock, Shares, Outstanding (in Shares)

21,430,611

'

'

'

'

21,430,611

17,906,937

'

'

'

'

'

'

'

'

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

'

'

'

'

'

'

'

'

'

'

28.00%

34.00%

'

'

'

Private Placement Units

'

'

'

'

'

'

'

'

4,800,000

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

2.55

2.1

'

3.125

'

'

'

'

'

'

'

'

2.5

2.5

Proceeds from Issuance of Private Placement

'

'

'

'

$12,000,000

'

'

'

'

'

'

'

'

'

'

Warrants Issued (in Shares)

'

'

'

'

96,000

'

'

'

'

'

'

'

'

'

'

Deferred Offering Costs

419,777

'

'

'

2,357,732

419,777

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

'

'

229,005

'

'

'

'

'

'

'

655,582

'

'

Derivative Liability, Fair Value, Gross Liability

'

328,350

407,558

'

12,655,582

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance or Sale of Equity

'

3,075,000

3,121,800

5,000,000

'

6,196,800

5,000,000

12,000,000

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

1,500,000

1,815,000

1,818,182

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

$2.05

$1.72

$2.75

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs

'

'

'

779,271

'

-857,278

-779,271

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

2,579,575

375,000

'

'

'

2,579,575

'

'

'

453,750

'

'

'

'

'

Warrants Exercisable Term

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Or Sale Of Equity Net Of Issuance Costs

'

2,500,000

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Stock Issuance Costs

'

467,989

389,289

'

'

836,099

779,271

'

'

'

'

'

'

'

'

Payments of Warrant Issuance Costs

'

57,525

57,531

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance (in Shares)

5,305,484

'

'

'

'

5,305,484

'

'

'

'

'

'

'

'

'

Registration Payment Arrangement, Maximum Potential Consideration

$16,800,000

'

'

'

'

$16,800,000

'

'

'

'

'

'

'

'

'

Commission Expense Or Discount From Sale Of Stock Proceeds

2.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_Options_Details

Note 11 - Options (Details) (USD $)	12 Months Ended				1 Months Ended	12 Months Ended		12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2013	Aug. 31, 2004	Nov. 30, 2013	28-May-10	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013
				Employee Stock Option [Member]	Performance Shares [Member]	Performance Shares [Member]	Restricted Stock Units (RSUs) [Member]	Employee Stock Option Plan [Member]	Non-Management Board Members [Member]	Employees [Member]	Maximum [Member]
				Employee Stock Option Plan [Member]	Two Executives [Member]
Note 11 - Options (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	'	'	'	'	'	'	'	10.00%	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	'	'	330,000	2,143,061	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,321,830	2,286,589	1,585,816	'	'	'	'	1,691,132	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	'	'	'	451,929	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'	'	'	'	'	'	'	'	'10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'3 years	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	391,000	955,000	328,000	'	2,763,940	'	'	'	391,000	955,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	276,394	'	'	'	'	1,658,364	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	$1,771,200	$2,214,000	'	'	'	'	'	'	'	'	'
Share-based Compensation (in Dollars)	1,153,882	2,323,845	702,460	'	'	442,800	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	3,500	0	25,000	'	'	3,500	'	'	'	'	'
Proceeds from Stock Options Exercised (in Dollars)	5,965	'	93,165	'	'	5,965	'	'	'	'	'
Stock Granted, Value, Share-based Compensation, Forfeited (in Dollars)	'	'	$7,302	'	'	'	'	'	'	'	'

Note_11_Options_Details_Fair_V

Note 11 - Options (Details) - Fair Value Assumptions of Option Awards (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Note 11 - Options (Details) - Fair Value Assumptions of Option Awards [Line Items]	'	'	'
The weighted average grant date fair value per options granted (in Dollars per share)	$1.05	$2.51	$1.84
Broker Options [Member]	'	'	'
Note 11 - Options (Details) - Fair Value Assumptions of Option Awards [Line Items]	'	'	'
Volatility	64.00%	64.70%	'
Risk-free interest rate	0.01%	0.08%	'
Expected life (in years)	'7 years	'10 years	'
Dividend yield	0.00%	0.00%	'
The weighted average grant date fair value per options granted (in Dollars per share)	$3.09	$2.51	'

Note_11_Options_Details_Stock_

Note 11 - Options (Details) - Stock Option Transactions (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2010	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
				Beginning [Member]	Beginning [Member]	Beginning [Member]	Ending [Member]	Ending [Member]	Ending [Member]
Note 11 - Options (Details) - Stock Option Transactions [Line Items]	'	'	'	'	'	'	'	'	'
Outstanding, beginning of period, (in Shares)	'	'	'	4,139,059	3,216,954	3,038,698	4,455,072	4,139,059	3,216,954
Outstanding, beginning of period,	'	'	'	$4.86	$5.33	$5.53	$3.97	$4.86	$5.33
Outstanding, beginning of period,	'	'	'	$2.76	$2.82	$2.87	'	'	'
Granted (in Shares)	391,000	955,000	328,000	'	'	'	'	'	'
Granted	$1.81	$3.27	$3.51	'	'	'	'	'	'
Granted	$1.05	$2.51	$1.84	'	'	'	'	'	'
Exercised (in Shares)	-3,500	0	-25,000	'	'	'	'	'	'
Exercised	$1.81	'	$3.73	'	'	'	'	'	'
Exercised	$0.09	'	$1.55	'	'	'	'	'	'
Forfeiture (in Shares)	-67,000	-32,862	-4,667	'	'	'	'	'	'
Expired (in Shares)	-4,487	-33	-120,077	'	'	'	'	'	'
Expired	$654.48	$69.74	$6.01	'	'	'	'	'	'
Expired	$403.93	$53.82	$1.61	'	'	'	'	'	'
Balance at end of period (in Shares)	4,455,072	'	'	4,139,059	3,216,954	3,038,698	4,455,072	4,139,059	3,216,954
Balance at end of period	$3.97	'	'	$4.86	$5.33	$5.53	$3.97	$4.86	$5.33
Balance at end of period	'	'	'	'	'	'	$2.21	$2.76	$2.82
Options exercisable, end of year (in Shares)	3,321,830	2,286,589	1,585,816	'	'	'	'	'	'
Options exercisable, end of year	$4.09	$5.94	$7.11	'	'	'	'	'	'
Options exercisable, end of year	$2.41	$3.55	$4.03	'	'	'	'	'	'

Note_11_Options_Details_Stock_1

Note 11 - Options (Details) - Stock Options Oustanding (USD $)	12 Months Ended			23 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013
				Under $2.50 [Member]	$2.51 - $5.00 [Member]	$5.01 - $7.50 [Member]	$7.51 - $10.00 [Member]	$10.01 - $100.00 [Member]	$300.00 - $500.00 [Member]	$500.01 - $1,000.00 [Member]	$1,000.01 - $1,500.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Exercise price	'	'	'	'	$2.51	$5.01	$7.51	$10.01	$300	$500.01	$1,000.01
Exercise price	'	'	'	$2.50	$5	$7.50	$10	$100	$500	$1,000	$1,500
Number outstanding (in Shares)	4,455,072	'	'	'	4,415,333	'	'	35,702	3,971	33	33
Options outstanding weighted average exercise price per share	$3.97	'	'	'	$3.38	'	'	$39.75	$331.15	$770.13	$1,149.13
Options outstanding weighted average remaining contract life (years)	'	'	'	'	'3 years 36 days	'	'	'3 years 317 days	'2 years 109 days	'1 year 105 days	'164 days
Options outstanding weighted average grant due fair value	'	'	'	'	$1.77	'	'	$31.19	$223.52	$493.31	$709.18
Options outstanding number exercisable (in Shares)	3,321,830	2,286,589	1,585,816	'	3,282,091	'	'	35,702	3,971	33	33
Options exercisable weighted average exercise price per share	$4.09	$5.94	$7.11	'	$3.28	'	'	$39.75	$331.15	$770.13	$1,149.13
Options exercisable weighted average grant date fair value	$2.41	$3.55	$4.03	'	$1.82	'	'	$31.19	$223.52	$493.31	$709.18

Note_11_Options_Details_Compon

Note 11 - Options (Details) - Components of Stock-Based Compensation Expense (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock based compensation expense components	$1,153,882	$2,323,845	$702,460
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock based compensation expense components	837,206	1,505,061	601,423
Selling, General and Administrative Expenses [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock based compensation expense components	$316,676	$818,784	$101,037

Note_12_Deferred_Share_Units_D

Note 12 - Deferred Share Units (Details) (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2013	28-May-10
				Deferred Share Units [Member]	Deferred Share Units [Member]
Note 12 - Deferred Share Units (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	110,000
Deferred Share Units to Non Management Board Members (in Dollars)	$39,547	$36,727	$33,101	$43,040	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	66,960	'

Note_12_Deferred_Share_Units_D1

Note 12 - Deferred Share Units (Details) - Deferred Share Units (Deferred Share Units [Member], USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Deferred Share Units [Member]	'	'	'
Note 12 - Deferred Share Units (Details) - Deferred Share Units [Line Items]	'	'	'
Additional paid in capital (in Dollars)	$39,547	$36,727	$33,101
Additional paid in capital (in Dollars)	$20,591	$12,199	$10,250
Accrued liability	9,181	9,688	6,569
Accrued liability	2,325	4,611	2,050

Note_14_Warrants_Details

Note 14 - Warrants (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Jan. 10, 2013

Nov. 30, 2013

Jul. 31, 2013

Mar. 31, 2013

Mar. 31, 2012

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

Jan. 31, 2011

Feb. 01, 2011

Nov. 30, 2013

Nov. 30, 2012

Feb. 01, 2011

Nov. 30, 2012

Feb. 01, 2011

Nov. 30, 2013

Jul. 31, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

Series A Common Share Purchase Warrant [Member]

Series A Common Share Purchase Warrant [Member]

Series A Common Share Purchase Warrant [Member]

Series B Common Share Purchase Warrant [Member]

Series B Common Share Purchase Warrant [Member]

Private Placement Offering [Member]

July 2013 Warrants [Member]

July 2013 Warrants [Member]

Cash Exercise Of Warrants [Member]

Cash Exercise Of Warrants [Member]

Cashless Exercise [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Note 14 - Warrants (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued

'

'

'

'

'

'

'

'

96,000

4,800,000

'

'

4,800,000

'

96,000

'

'

'

'

'

'

'

'

Warrants Exercisable Term

'

'

'5 years

'5 years

'

'

'

'

'

'5 years

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

2.55

2.1

'

'

'

'

3.125

2.5

2.5

'

2.5

'

3.125

2.55

'

'

'

'

'

'

'

Warrants and Rights Outstanding (in Dollars)

'

$5,438,022

$328,350

$407,558

'

$5,438,022

$1,960,893

$6,611,015

'

$7,214,366

'

'

$5,441,216

'

$229,005

$493,947

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

46.60%

64.60%

62.40%

63.00%

'

'

'

'

'

70.00%

67.93%

54.90%

59.00%

48.20%

67.00%

55.51%

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

0.26%

0.12%

0.58%

0.40%

'

'

'

'

'

0.99%

0.12%

0.37%

0.29%

0.18%

0.99%

0.64%

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'2 years

'1 year 36 days

'5 years

'5 years

'

'4 years

'

'

'

'5 years

'2 years 73 days

'3 years 36 days

'2 years

'73 days

'3 years

'4 years 255 days

'

'

'

'

'

'

'

Proceeds from Issuance or Sale of Equity (in Dollars)

'

'

3,075,000

3,121,800

5,000,000

6,196,800

5,000,000

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

1,500,000

1,815,000

1,818,182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

$2.05

$1.72

$2.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

'

'

'

0.25

'

'

'

'

'

'

'

'

'

'

'

'

0.25

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

6,360,300

'

'

'

6,360,300

7,286,000

8,979,275

'

'

3,670,000

3,720,000

'

3,470,000

'

870,000

'

'

'

'

'

'

'

Warrants Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

770,700

150,000

1,300,000

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

205,175

75,000

105,315

'

'

'

Fair Value of Warrants Exercised (in Dollars)

'

'

'

'

'

'

'

'

'

'

980,382

1,005,692

'

'

'

'

'

'

'

'

'

'

'

Change in Fair Value Warrants (in Dollars)

'

'

'

'

'

($3,356,534)

[1]

$3,841,233

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

($3,356,534)

$3,841,233

$5,346,878

[1]

The total net loss related to the conversion option and warrant liability has been recorded under fair value adjustment derivative liabilities on the consolidated statements of operations and comprehensive loss.

Note_14_Warrants_Details_Warra

Note 14 - Warrants (Details) - Warrants Outstanding and Exercisable

Nov. 30, 2013

Jul. 31, 2013

Mar. 31, 2013

Nov. 30, 2012

Nov. 30, 2011

Jan. 31, 2011

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

Feb. 01, 2011

Nov. 30, 2013

Nov. 30, 2013

Agent Warrants [Member]

Agent Warrants [Member]

Series A Common Share Purchase Warrant [Member]

Series A Common Share Purchase Warrant [Member]

Series A Common Share Purchase Warrant [Member]

March 2013 Warrants [Member]

July 2013 Warrants [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price (in Dollars per Item)

'

2.55

2.1

'

'

3.125

3.125

'

2.5

'

2.5

2.1

2.55

Number Outstanding

6,360,300

'

'

7,286,000

8,979,275

'

96,000

96,000

3,670,000

3,720,000

'

1,724,300

870,000

Expiry

'

'

'

'

'

'

'March 30, 2014

'

'February 1, 2016

'

'

'March 22, 2018

'July 31, 2018

Shares Issuable Upon Exercise

2,579,575

375,000

'

'

'

'

96,000

'

1,835,000

'

'

431,075

217,500

Note_14_Warrants_Details_Warra1

Note 14 - Warrants (Details) - Warrant Transactions

12 Months Ended

12 Months Ended

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

March 2013 Warrants [Member]

July 2013 Warrants [Member]

May 07 Warrants [Member]

Note 14 - Warrants (Details) - Warrant Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, December 1, 2012

7,286,000

8,979,275

3,720,000

4,695,000

3,470,000

3,945,000

96,000

96,000

96,000

'

'

243,275

Issued

3,315,000

'

'

'

'

'

'

'

'

1,815,000

1,500,000

'

Exercised

-770,700

-1,450,000

-50,000

-975,000

'

-475,000

'

'

'

-90,700

-630,000

'

Expired

-3,470,000

-243,275

'

'

-3,470,000

'

'

'

'

'

'

-243,275

Outstanding, November 30, 2013

6,360,300

7,286,000

3,670,000

3,720,000

'

3,470,000

96,000

96,000

96,000

1,724,300

870,000

'

Note_14_Warrants_Details_Fair_

Note 14 - Warrants (Details) - Fair Market Value of Warrants (USD $)	Nov. 30, 2013	Jul. 31, 2013	Mar. 31, 2013	Nov. 30, 2012	Nov. 30, 2011
Note 14 - Warrants (Details) - Fair Market Value of Warrants [Line Items]	'	'	'	'	'
Class of warrant outstanding	$5,438,022	$328,350	$407,558	$1,960,893	$6,611,015
Series B Warrants [Member]	'	'	'	'	'
Note 14 - Warrants (Details) - Fair Market Value of Warrants [Line Items]	'	'	'	'	'
Class of warrant outstanding	'	'	'	276,038	'
Placement Agent Warrants [Member]	'	'	'	'	'
Note 14 - Warrants (Details) - Fair Market Value of Warrants [Line Items]	'	'	'	'	'
Class of warrant outstanding	112,550	'	'	25,363	'
Series A Warrants [Member]	'	'	'	'	'
Note 14 - Warrants (Details) - Fair Market Value of Warrants [Line Items]	'	'	'	'	'
Class of warrant outstanding	3,790,736	'	'	1,659,492	'
March 2013 Warrants [Member]	'	'	'	'	'
Note 14 - Warrants (Details) - Fair Market Value of Warrants [Line Items]	'	'	'	'	'
Class of warrant outstanding	1,040,788	'	'	'	'
July 2013 Warrants [Member]	'	'	'	'	'
Note 14 - Warrants (Details) - Fair Market Value of Warrants [Line Items]	'	'	'	'	'
Class of warrant outstanding	$493,947	'	'	'	'

Note_14_Warrants_Details_Fair_1

Note 14 - Warrants (Details) - Fair Value Assumptions for Warrants

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jan. 10, 2013

Nov. 30, 2013

Jul. 31, 2013

Mar. 31, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2011

Nov. 30, 2013

Nov. 30, 2012

Feb. 01, 2011

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Feb. 01, 2011

Nov. 30, 2012

Agent Warrants [Member]

Agent Warrants [Member]

Series A Common Share Purchase Warrant [Member]

Series A Common Share Purchase Warrant [Member]

Series A Common Share Purchase Warrant [Member]

March 2013 Warrants [Member]

July 2013 Warrants [Member]

Series B Common Share Purchase Warrant [Member]

Series B Common Share Purchase Warrant [Member]

Note 14 - Warrants (Details) - Fair Value Assumptions for Warrants [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number outstanding (Shares) (in Shares)

'

6,360,300

'

'

6,360,300

7,286,000

8,979,275

96,000

96,000

'

3,670,000

3,720,000

1,724,300

870,000

'

3,470,000

Volatility %

46.60%

64.60%

62.40%

63.00%

'

'

'

86.51%

46.15%

70.00%

67.93%

54.90%

54.84%

55.51%

59.00%

48.20%

Risk-free rate %

0.26%

0.12%

0.58%

0.40%

'

'

'

0.12%

0.18%

0.99%

0.12%

0.37%

0.64%

0.64%

0.29%

0.18%

Expected life Years

'2 years

'1 year 36 days

'5 years

'5 years

'4 years

'

'

'73 days

'1 year 36 days

'5 years

'2 years 73 days

'3 years 36 days

'4 years 109 days

'4 years 255 days

'2 years

'73 days

Note_15_Income_Taxes_Details

Note 15 - Income Taxes (Details) (USD $)	Nov. 30, 2013	Nov. 30, 2012
Note 15 - Income Taxes (Details) [Line Items]	'	'
Tax Credit Carryforward, Amount	$179,551	$301,932
Federal SR & ED Expenditures [Member]	'	'
Note 15 - Income Taxes (Details) [Line Items]	'	'
Tax Credit Carryforward, Amount	10,310,000	9,822,000
Ontario Harmonization Credits [Member]	'	'
Note 15 - Income Taxes (Details) [Line Items]	'	'
Tax Credit Carryforward, Amount	400,000	427,000
Unclaimed ITCs [Member]	'	'
Note 15 - Income Taxes (Details) [Line Items]	'	'
Tax Credit Carryforward, Amount	$2,325,000	$2,089,000

Note_15_Income_Taxes_Details_I

Note 15 - Income Taxes (Details) - Income Tax Reconciliation (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Income Tax Reconciliation [Abstract]	'	'	'
Statutory income tax rate	26.50%	27.00%	28.00%
Statutory income tax recovery	($3,046,180)	($1,632,406)	($1,366,478)
Non-deductible expenses/ non-taxable income	1,446,008	-399,748	-1,324,979
Change in valuation allowance	1,248,045	3,217,198	2,452,926
Investment tax credit	-164,308	-561,988	'
Financing costs booked to equity	-307,262	'	'
Ontario tax rate change	'	-420,990	'
Foreign exchange change	746,667	-230,695	'
True up of tax returns, etc.	77,030	28,629	238,531
	$0	$0	$0

Note_15_Income_Taxes_Details_D

Note 15 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Deferred tax assets	'	'	'
Non-capital loss carry-forwards	$6,831,991	$6,031,917	$4,147,325
Book and tax basis differences on assets and liabilities	992,378	773,590	824,640
Other	37,136	17,590	8,635
Ontario harmonization tax credit	399,831	427,355	361,888
Investment tax credit	2,324,856	2,089,238	1,351,859
Undeducted research and development expenditures	2,180,640	2,179,097	1,607,242
	12,766,832	11,518,787	8,301,589
Valuation allowances for deferred tax assets	-12,766,832	-11,518,787	-8,301,589
Net deferred tax assets	$0	$0	$0

Note_15_Income_Taxes_Details_S

Note 15 - Income Taxes (Details) - Summary of Operating Losses (USD $)

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2033

Nov. 30, 2032

Nov. 30, 2031

Nov. 30, 2030

Nov. 30, 2029

Nov. 30, 2028

Nov. 30, 2027

Nov. 30, 2026

Nov. 30, 2025

Nov. 30, 2014

Nov. 30, 2013

Nov. 30, 2026

Nov. 30, 2025

Nov. 30, 2024

Total For Canada [Member]

Total For Internal Revenue Service [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Canada [Member]

Internal Revenue Service (IRS) [Member]

Internal Revenue Service (IRS) [Member]

Internal Revenue Service (IRS) [Member]

Canada [Member]

Internal Revenue Service (IRS) [Member]

Note 15 - Income Taxes (Details) - Summary of Operating Losses [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax losses expiring in the year ended November 30

($25,697,851)

$86,714

($5,165,818)

($5,380,452)

($4,938,324)

($3,629,479)

($597,768)

($808,024)

($1,372,624)

$0

($513,476)

($2,129,847)

($1,162,039)

$34,523

$16,234

$35,957

Note_16_Contingencies_Details

Note 16 - Contingencies (Details) (Indemnification Agreement [Member], CAD)	Nov. 30, 2013
Note 16 - Contingencies (Details) [Line Items]	'
Guarantor Obligations, Maximum Exposure, Undiscounted	1,455,000
Threshold Amount [Member]	'
Note 16 - Contingencies (Details) [Line Items]	'
Guarantor Obligations, Maximum Exposure, Undiscounted	50,000

Note_17_Financial_Instruments_1

Note 17 - Financial Instruments (Details)	0 Months Ended	1 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Jan. 10, 2013	Nov. 30, 2013	Jul. 31, 2013	Mar. 31, 2013	Nov. 30, 2013	Nov. 30, 2013	Nov. 30, 2013
						Base Amount for Exchange Rate [Member]	Base Amount for Exchange Rate [Member]
						USD ($)	CAD
Note 17 - Financial Instruments (Details) [Line Items]	'	'	'	'	'	'	'
Fair Value Assumptions, Expected Term	'2 years	'1 year 36 days	'5 years	'5 years	'4 years	'	'
Foreign Exchange Risk Threshold Balance (in Dollars)	'	'	'	'	'	'	1
Foreign Exchange Risk Movement In Currency Percentage	'	'	'	'	10.00%	'	'
Foreign Exchange Risk Loss And Other Comprehensive Loss Amount Affected (in Dollars)	'	'	'	'	'	$0.10	'

Note_17_Financial_Instruments_2

Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis (USD $)	Nov. 30, 2013		Nov. 30, 2012		Nov. 30, 2011
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(a) Cash and cash equivalents	$760,586		$497,016		'
(b) Convertible debt1	1,290,683	[1]	'	[1]	'
(c) Warrant liabilities2	6,166,972		1,960,893		6,611,015
Total	6,927,558		2,457,909		'
Conversion Option [Member] | Fair Value, Inputs, Level 1 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(b) Convertible debt1	'	[2]	'		'
Conversion Option [Member] | Fair Value, Inputs, Level 2 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(b) Convertible debt1	'	[2]	'		'
Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(b) Convertible debt1	728,950	[2]	'		'
Conversion Option [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(b) Convertible debt1	728,950	[2]	'		'
Warrant [Member] | Fair Value, Inputs, Level 1 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(c) Warrant liabilities2	'	[3]	'	[3]	'
Warrant [Member] | Fair Value, Inputs, Level 2 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(c) Warrant liabilities2	'	[3]	'	[3]	'
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(c) Warrant liabilities2	5,438,022	[3]	1,960,893	[3]	'
Warrant [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(c) Warrant liabilities2	5,438,022	[3]	1,960,893	[3]	'
Fair Value, Inputs, Level 1 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
(a) Cash and cash equivalents	760,586		497,016		'
Total	760,586		497,016		'
Fair Value, Inputs, Level 3 [Member]	'		'		'
Note 17 - Financial Instruments (Details) - Fair Values of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'		'		'
Total	$6,166,972		$1,960,893		'
[1]	The Company calculates the interest rate for the convertible debt and due to related parties based on the Company's estimated cost of raising capital and uses the discounted cash flow model to calculate the fair value of the convertible debt and the amounts due to related parties.
[2]	Conversion options are included in the convertible debenture on the consolidated balance sheet.
[3]	Warrant liabilities are included on the consolidated balance sheet.

Note_17_Financial_Instruments_3

Note 17 - Financial Instruments (Details) - Key Unobservable Inputs Related to Valuing Conversion Option and Warrant Liabilities (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Jan. 10, 2013

Nov. 30, 2013

Jul. 31, 2013

Mar. 31, 2013

Nov. 30, 2012

Nov. 30, 2011

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2012

Black-Scholes [Member]

Black-Scholes [Member]

Black-Scholes [Member]

Black-Scholes [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Convertible Debt 1[Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Minimum [Member]

Maximum [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value Inputs, Assets, Quantitative Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value - conversion (in Dollars)

'

$1,290,683

[1]

'

'

'

[1]

'

$728,950

$5,422,560

'

'

'

'

'

'

Unobservable input

'

'

'

'

'

'

0.12%

'

0.12%

0.64%

'

'

'

'

Fair value - conversion (in Dollars)

'

$6,166,972

'

'

$1,960,893

$6,611,015

'

'

'

'

$5,438,022

[2]

$1,960,893

[2]

$5,438,022

[2]

$1,960,893

[2]

Unobservable input

46.60%

64.60%

62.40%

63.00%

'

'

64.60%

'

54.00%

87.00%

'

'

'

'

[1]

The Company calculates the interest rate for the convertible debt and due to related parties based on the Company's estimated cost of raising capital and uses the discounted cash flow model to calculate the fair value of the convertible debt and the amounts due to related parties.

[2]

Warrant liabilities are included on the consolidated balance sheet.

Note_17_Financial_Instruments_4

Note 17 - Financial Instruments (Details) - Reconciliation of Level 3 Fair Value Measurements (USD $)	1 Months Ended	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2013		Nov. 30, 2012		Nov. 30, 2011	Jul. 31, 2013	Mar. 31, 2013	Jan. 10, 2013
Reconciliation of Level 3 Fair Value Measurements [Abstract]	'	'		'		'	'	'	'
Opening balance - Conversion Option	'	$1,960,893		$6,611,015		'	$328,350	$407,558	'
Opening balance - Total	'	1,960,893		6,611,015		'	'	'	'
Total gains or losses:	'	'		'		'	'	'	'
- in net loss(a) - Conversion Option	533,149	533,149	[1]	'	[1]	'	'	'	'
- in net loss(a) - Warrant Liability	'	3,356,534	[1]	-3,841,233	[1]	'	'	'	'
- in net loss(a) - Total	'	3,889,683	[1]	-3,841,233	[1]	-5,346,878	'	'	'
- translation adjustments - Conversion Option	'	-24,299		'		'	'	'	'
- translation adjustments - Warrant Liability	'	-449,224		-20,026		'	'	'	'
- translation adjustments - Total	'	-473,523		-20,026		'	'	'	'
Purchases - Conversion Option	'	220,100		'		'	'	'	'
Purchases - Warrant Liability	'	735,908		'		'	'	'	'
Purchases - Total	'	956,008		'		'	'	'	'
Exercise - Warrant Liability	'	-166,089		-788,863		'	'	'	'
Exercise - Total	'	-166,089		-788,863		'	'	'	'
Closing balance - Conversion Option	728,950	728,950		'		'	'	'	220,100
Closing balance - Warrant Liability	5,438,022	5,438,022		1,960,893		6,611,015	328,350	407,558	'
Closing balance - Total	$6,166,972	$6,166,972		$1,960,893		$6,611,015	'	'	'
[1]	The total net loss related to the conversion option and warrant liability has been recorded under fair value adjustment derivative liabilities on the consolidated statements of operations and comprehensive loss.

Note_17_Financial_Instruments_5

Note 17 - Financial Instruments (Details) - Fair Value of Financial Assets and Financial Liabilities Not Measured on a Recurring Basis (USD $)	Nov. 30, 2013		Nov. 30, 2012
Fair Value of Financial Assets and Financial Liabilities Not Measured on a Recurring Basis [Abstract]	'		'
Due to related parties(iii)	$759,564	[1]	$783,717	[1]
Due to related parties(iii)	515,130	[1]	531,510	[1]
Convertible debt(iii)	1,376,456	[1]	'	[1]
Convertible debt(iii)	$1,290,683	[1]	'	[1]
[1]	The Company calculates the interest rate for the convertible debt and due to related parties based on the Company's estimated cost of raising capital and uses the discounted cash flow model to calculate the fair value of the convertible debt and the amounts due to related parties.

Note_17_Financial_Instruments_6

Note 17 - Financial Instruments (Details) - Cash and Cash Equivalents (USD $)	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2010
Cash and Cash Equivalents [Abstract]	'	'	'	'
Cash	$760,586	$447,016	'	'
Bankers acceptance (30 days maturity, interest 0.10%)	'	50,000	'	'
Total cash and cash equivalents	$760,586	$497,016	$4,817,088	$789,136

Note_17_Financial_Instruments_7

Note 17 - Financial Instruments (Details) - Cash and Cash Equivalents (Parentheticals)	Nov. 30, 2013	Nov. 30, 2012
Cash and Cash Equivalents [Abstract]	'	'
Bankers acceptance, interest rate	0.10%	0.10%

Note_17_Financial_Instruments_8

Note 17 - Financial Instruments (Details) - Accounts Receivable Aging (USD $)	Nov. 30, 2013	Nov. 30, 2012
Accounts Receivable Aging [Abstract]	'	'
Total accounts receivable	$1,475,745	$2,778
Less allowance for doubtful accounts	0	0
Total accounts receivable, net	1,475,745	2,778
Not past due	1,473,097	2,778
Past due for more than 31 days but no more than 60 days	$2,648	'

Note_17_Financial_Instruments_9

Note 17 - Financial Instruments (Details) - Foreign Exchange Rates

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

USD ($)

CAD

USD ($)

CAD

Cash [Member]

Cash [Member]

Cash [Member]

Cash [Member]

Accounts Payable [Member]

Accounts Payable [Member]

Accounts Payable [Member]

Accounts Payable [Member]

Employee Cost Payable [Member]

Employee Cost Payable [Member]

Employee Cost Payable [Member]

Employee Cost Payable [Member]

Capital Lease [Member]

Capital Lease [Member]

Capital Lease [Member]

Capital Lease [Member]

Due to Related Party [Member]

Due to Related Party [Member]

Due to Related Party [Member]

Due to Related Party [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Note 17 - Financial Instruments (Details) - Foreign Exchange Rates [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

FX rates used to translate to U.S.

1.062

1.062

0.9936

0.9936

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset reporting currency denominated value

$434,089

461,002

$248,991

247,397

$434,089

461,002

$248,991

247,397

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liability reporting currency denominated value

1,431,142

1,519,873

1,312,404

1,304,005

'

'

'

'

456,025

484,299

286,561

284,727

172,288

182,970

190,603

189,383

43,265

45,947

51,524

51,194

759,564

806,657

783,716

778,701

Net exposure

($997,053)

-1,058,871

($1,063,413)

-1,056,608

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recovered_Sheet1

Note 17 - Financial Instruments (Details) - Contractual Maturities of the Undiscounted Cash Flows of Financial Liabilities (USD $)	12 Months Ended
	Nov. 30, 2013
Third parties	'
Undiscounted future cash flows	$3,816,486
Accounts Payable [Member]	'
Third parties	'
Undiscounted future cash flows	810,381
Accounts Payable [Member] | Less Than 3 Months [Member]	'
Third parties	'
Undiscounted future cash flows	810,381
Lease Obligations [Member]	'
Third parties	'
Undiscounted future cash flows	43,264
Lease Obligations [Member] | Less Than 3 Months [Member]	'
Third parties	'
Undiscounted future cash flows	13,189
Lease Obligations [Member] | 3 to 6 Months [Member]	'
Third parties	'
Undiscounted future cash flows	13,676
Lease Obligations [Member] | 6 to 9 Months [Member]	'
Third parties	'
Undiscounted future cash flows	14,198
Lease Obligations [Member] | 9 Months to 1 Year [Member]	'
Third parties	'
Undiscounted future cash flows	2,201
Employee Cost Payable [Member]	'
Third parties	'
Undiscounted future cash flows	508,616
Employee Cost Payable [Member] | Less Than 3 Months [Member]	'
Third parties	'
Undiscounted future cash flows	508,616
Due to Related Party [Member]	'
Third parties	'
Undiscounted future cash flows	759,564
Due to Related Party [Member] | Less Than 3 Months [Member]	'
Third parties	'
Undiscounted future cash flows	759,564
Unsecured Convertible Debentures [Member]	'
Third parties	'
Undiscounted future cash flows	1,694,661
Unsecured Convertible Debentures [Member] | Less Than 3 Months [Member]	'
Third parties	'
Undiscounted future cash flows	44,353
Unsecured Convertible Debentures [Member] | 3 to 6 Months [Member]	'
Third parties	'
Undiscounted future cash flows	44,353
Unsecured Convertible Debentures [Member] | 6 to 9 Months [Member]	'
Third parties	'
Undiscounted future cash flows	45,339
Unsecured Convertible Debentures [Member] | 9 Months to 1 Year [Member]	'
Third parties	'
Undiscounted future cash flows	44,846
Unsecured Convertible Debentures [Member] | Greater Than 1 Year [Member]	'
Third parties	'
Undiscounted future cash flows	1,515,770
Less Than 3 Months [Member]	'
Third parties	'
Undiscounted future cash flows	2,136,103
3 to 6 Months [Member]	'
Third parties	'
Undiscounted future cash flows	58,029
6 to 9 Months [Member]	'
Third parties	'
Undiscounted future cash flows	59,537
9 Months to 1 Year [Member]	'
Third parties	'
Undiscounted future cash flows	47,047
Greater Than 1 Year [Member]	'
Third parties	'
Undiscounted future cash flows	$1,515,770

Note_18_Segmented_Information_1

Note 18 - Segmented Information (Details) - Information by Geographic Segment (USD $)	12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
United States	$1,527,474	$107,091	$501,814
	1,527,474	107,091	501,814
Canada	4,379,501	2,474,878	'
Canada	1,231,309	1,535,703	'
UNITED STATES	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
United States	1,527,474	107,091	501,814
CANADA	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Canada	4,379,501	2,474,878	6,247,228
Canada	$1,231,309	$1,535,703	$951,914

Note_19_Restatement_of_Compara2

Note 19 - Restatement of Comparative Amounts (Details) - Impact of the Restatement Adjustments (USD $)	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2012	Nov. 30, 2011	Nov. 30, 2012	Nov. 30, 2011
			Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Scenario, Adjustment [Member]	Scenario, Adjustment [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]
Capital stock	$11,721,152	$6,128,697	$147,152	$147,152	$5,981,545	$755,124	$6,128,697	$902,276
Additional paid in capital	$23,619,055	$22,428,120	$28,409,665	$20,822,672	($5,981,545)	($755,124)	$22,428,120	$20,067,548

Note_20_Subsequent_Events_Deta

Note 20 - Subsequent Events (Details) (USD $)	1 Months Ended			12 Months Ended		3 Months Ended
	Jul. 31, 2013	Mar. 31, 2013	Mar. 31, 2012	Nov. 30, 2013	Nov. 30, 2012	Feb. 28, 2014	Nov. 30, 2013
						Subsequent Event [Member]	Unsecured Convertible Debentures [Member]
Note 20 - Subsequent Events (Details) [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	1,500,000	1,815,000	1,818,182	'	'	1,312,100	'
Proceeds from Issuance of Common Stock	'	'	'	'	'	$4,808,054	'
Payments for Commissions	'	'	'	'	'	135,960	'
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	'	'	779,271	-857,278	-779,271	419,777	'
Deferred Finance Costs, Noncurrent, Net	'	'	'	'	'	'	$419,777